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ABSTRACT 
 
Cardiovascular disease is one of the main causes of mortality and one of the significant 
burdens to society.  Major cardiovascular diseases such as acute myocardial infarction (heart 
attack), heart failure and cardiac arrhythmia often result in the development of 
ischemia/reperfusion (I/R) injury. 
Untreated I/R injury is known to cause cardiac contractile dysfunction.  It is established 
that matrix metalloproteinase-2 (MMP-2) is activated and degrades contractile proteins 
during I/R, and many other factors including metabolic enzymes, kinases and structural 
proteins are affected by I/R.  However, the molecular mechanisms responsible for these 
changes are unclear.    
Since MMP-2 is known to its broad spectrum of action, I hypothesize that, in addition to 
contractile proteins, proteins related to regulation of energy metabolism are MMP-2 targets 
during I/R, and protein kinase such as myosin light chain kinase (MLCK) is also involved in 
this process. The use of proteomics in studying heart injury triggered by I/R will reveal new 
potential targets for pharmacological protection of heart from I/R induced contractile 
dysfunction. In addition, selective inhibition of MMP-2 using MMP-2 siRNA protects the 
heart from I/R injury. 
In this study, we investigated the protein modulation during I/R using proteomic 
approach.  In order to study the effect of protein kinases (MLCK) and MMP-2, their selective 
inhibitors were used to inhibit those factors and evaluate the changes in energy metabolic 
proteins during I/R.    
          Proteomic analysis revealed that six proteins are involved in energy metabolism: ATP 
synthase β subunit, cytochrome b-c1 complex subunit 1, 24-kDa mitochondrial NADH 
dehydrogenase, NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, cytochrome c 
oxidase subunit, and succinyl-CoA ligase subunit, resulting in decreased levels in I/R hearts.  
The data suggests that energy metabolic proteins, especially the metabolic enzymes involved 
in the electron transport chain in the mitochondria may contribute to I/R injury.  In addition, 
our data provides evidence that the right and left ventricles of the heart respond differently to 
I/R injury, in terms of the regulation of contractile proteins and energy metabolic enzymes.  
         Studies using MLCK inhibitor, ML-7, and MMP-2 inhibitor, MMP-2 siRNA to 
investigate the effect of myosin light chain kinase (MLCK) and MMP-2 in energy metabolic 
proteins have shown that succinyl-CoA ligase and ATP synthase are affected by MLCK and 
MMP-2 respectively.  These results demonstrate that the effect of inhibition of the MLCK 
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and MMP-2 involves optimization of energy metabolism in I/R injury, likely resulting in 
increased energy production.  Hence, the observed proteins increase in cardiac recovery after 
I/R.   Also, inhibition of MLCK and MMP-2 by ML-7 and MMP-2 respectively shows cardio 
protective effect during I/R.   
         In summary, this study provides a novel pathogenesis in the development of I/R-
induced cardiac contractile dysfunction.  Moreover, we suggest a new therapeutic approach 
whereby using MMP-2 siRNA can be a promising gene therapy in the development of new 
preventive or treatment strategies against I/R injury. 
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1.1  Cardiovascular disease 
 
1.1.1 Facts of cardiovascular disease 
            Cardiovascular diseases include dysfunctional conditions of the heart and the vascular 
system supplying oxygen and nutrients to vital, life-sustaining areas of the body, such as the 
brain, the heart itself and other organs.  The likelihood of developing cardiovascular disease 
increases with different risk factors, such as aging, smoking, stress, physical inactivity, 
overweight, excessive alcohol consumption, air pollution, high blood pressure (hypertension), 
high blood cholesterol and diabetes. (2).  The global epidemic of cardiovascular disease still 
remains the number one cause of death around the world (3).  In the year of 2012, an estimate 
of 17.3 million people died from cardiovascular diseases, contributing to about 30% of all 
deaths in the world (4).  By the year 2030, it is predicted that around 23.3 million people will 
die from cardiovascular diseases (5).  In Canada, heart disease and stroke are two of the three 
leading causes of death.  Every 7 minutes, at least one Canadian dies from heart disease and 
stroke (1, 4, 6).  Cardiovascular disease is also the leading economic burden of disease in 
Canada, with a total direct cost (hospital care, drugs, physician care, other institutional care, 
etc.) of CDN$6.8 billion and an indirect cost (relating to mortality, and short and long term 
disability) of CDN$11.6 billion (7-8).  Therefore, cardiovascular disease is a major burden on  
society, accounting for more deaths, disability and health care costs than any other disease. 
 
1.1.2 Classification of cardiovascular diseases 
            Several methods have classified cardiovascular diseases into different groups.  A 
commonly used classification demonstrates that cardiovascular diseases manifest in six forms 
including:  
• coronary heart disease – disorder of the blood vessels supplying the heart muscle;  
• cerebrovascular disease - disorder of the blood vessels supplying the brain; 
• peripheral arterial disease – disorder of blood vessels supplying the arms and legs; 
• rheumatic heart disease – damage to the heart muscle and heart valves from rheumatic 
fever, caused by streptococcal bacteria; 
• congenital heart disease – prenatal malformations of heart structure; 
• deep vein thrombosis and pulmonary embolism – blood clots in the leg veins, which 
can be dislodged and can move to the heart and lungs.  (4) 
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              Among these six forms of cardiovascular diseases, coronary heart disease is the most 
common type covering 60% of all cardiovascular disease, causing the most death in the world 
(9).  Coronary heart disease is caused by the narrowing or blockage of coronary arteries and 
thus the reduction in blood supply of the heart muscle.  There are different pathological 
reasons causing the narrowing and blockage of the blood vessels including arteriosclerosis, 
vasospasm and atherosclerosis.  However, atherosclerosis is the major cause of coronary 
heart disease.  Atherosclerosis results from the accumulation of cholesterol, triglycerides and 
low-density lipoprotein in the arteries, triggering a chronic inflammatory response to generate 
plaques, and hence, narrowing the arteries.  With the age increases, the plaques become 
thicker and eventually cause the blockage of the artery, and ischemia of the heart occurs.  
Untreated ischemia of the heart leads to severe damage to the cardiac tissue.  Even after 
reperfusion, the damaged myocardium cannot be recovered.  This is the classic pathway that 
I/R injury induces myocardium infarction, and causes contractile dysfunction, and this 
eventually leads to heart failure.  Most of the cardiologists believe that it is the major reason 
that patients die from coronary heart disease.   
1.2   Ischemia/reperfusion injury (I/R injury) 
 
            Ischemia/reperfusion (I/R) injury is a multifaceted event that encompasses several 
distinct mechanisms leading to a worsening of cardiac function (10).  There are two 
pathological processes in I/R injury, which are ischemic injury and reperfusion injury.  
Ischemia is characterized by the lack of an efficient supply of oxygenated and nutrient-rich 
blood to a tissue or organ.  Reperfusion is the restoration of blood supply to the previously 
ischemic area. Some studies indicate that I/R injury only means reperfusion injury (11), while 
others think that it is incorrect to make that assumption (12).  There are different mechanisms 
between ischemic injury and reperfusion injury in terms of reactive oxygen species 
generation (13), inflammatory response (14) and damage of energy metabolism system (13).  
Therefore, ischemia/reperfusion injury should be considered as two different processes with a 
close relationship to each other. 
 
 
1.2.1 Ischemic injury 
            The general definition of ischemia is the reduction in blood flow in the tissue.  Many 
pathological conditions can trigger ischemia, such as atherosclerosis and thrombus blockage.  
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Reduction in the blood flow leads to oxygen transportation dysfunction and causes the 
shortage of oxygen in the tissue and cells.  When oxygen concentration in the tissue drops 
significantly, oxidative phosphorylation cannot occur, and this will result in reduced ATP 
formation in the mitochondria.  Cardiomyocytes have much more mitochondria than most of 
the cell types in the body because of the great need of energy to perform their function.  ATP 
formation is the most vital part for the cardiomyocyte contraction and survival.  During 
ischemia in the heart, the lack of oxygen in the myocardium will result in respiratory chain 
dysfunction, energy production disorder and reactive oxygen species (15) generation, which 
will then eventually lead to severe, irreversible damage to the cardiac tissue and a serious 
impact on the cardiac contractile function.  A common therapeutic strategy for ischemic 
injury is the reperfusion therapy.  However, both reperfusion therapy and self-reperfusion 
would potentially cause another different pathological process, namely reperfusion injury.   
 
1.2.2 Reperfusion injury 
            Reperfusion injury is the tissue damage caused by newly returning blood flow to 
previously ischemic tissue.  When the blood returns to the ischemic tissue, the restoration of 
the blood flow further damages the ischemic tissue.  The absence of oxygen and nutrients 
during ischemia creates a condition in which the restoration of oxygen and nutrients result in 
inflammation and oxidative damage through the induction of oxidative stress.  In the 
therapeutic strategy for I/R injury, such as coronary artery disease induced myocardium 
infarction (MI), reperfusion therapy is still the fundamental treatment for more than twenty 
years (16).  It has been widely accepted that ischemic injury is more severe than reperfusion, 
in terms of the tissue damage, causing that reperfusion injury has been overshadowed by 
ischemic injury.  There are only a few studies or clinical trials focus on the treatment and 
prevention of reperfusion injury (17).  However, ischemic injury and reperfusion injury 
should be considered as two inseparable processes and therapeutic approaches should be 
developed to treat both and thus may result in more effective recovery for the patient. 
 
1.2.3 Mechanism of ischemia/reperfusion injury 
            Ischemia/reperfusion injury has been studied for more than half a century; however, 
the underlying molecular mechanisms involved in the pathogenesis of myocardial I/R injury 
are complicated and involve the interactions of different pathways that are still unclear.  A 
multitude of mediators triggered by ischemia and/or reperfusion have been identified and 
range from inflammation (14), energy metabolism (13), cell death (18-19), and many others.  
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Limited supply of oxygen and nutrients for the maintenance of normal cardiac function 
during ischemia and the generation of oxidative stress during reperfusion might be the main 
reasons for the following consequence.  There is a growing body of evidence over the last 
decade pointing out that the degradation of functional proteins triggered by I/R-dependent 
ROS generation could be the fundamental molecular mechanism for ischemia/reperfusion 
injury.  It has been shown that several mediators and pathways, such as contractile proteins 
(20-21), MMPs (22), kinase (23) and energy metabolism proteins (24) are involved in this 
mechanism.  However, more studies are still needed in search of better targets for the 
therapeutic strategies of ischemia/reperfusion injury. 
 
1.3   Cardiac contractile proteins 
 
           In the cardiovascular system, the heart is most important organ for the circulation and 
is responsible for supplying blood flow to meet the metabolic demands of the organs and 
removing metabolic waste.  The heart has been considered as a pump in the circulation, and 
its physiological function highly depends on the contractile machinery of the heart.   In order 
to study the function and mechanism of cardiac contractile machinery, investigators focus on 
the cardiac sarcomere in the heart.  The cardiac sarcomere is the basic unit of muscle 
contraction in the heart.  The sarcomere is composed of thick and thin filaments.  Physical 
and chemical interaction between the thick and thin filaments result in the shortening of the 
sarcomere, and that is what we call the contraction of the heart (25).  There are different 
proteins performing various functions in both thick and thin filaments.  The thick filament is 
mainly comprised of myosin, and the thin filament is comprised of troponin, actin and 
tropomyosin.  These cardiac contractile proteins have been studied for decades and the 
physiological functions of each protein have been identified (26).  However, how cardiac 
contractile proteins are regulated in the pathological conditions is still unclear.  Recently, the 
regulatory subunits of myosin and myosin light chains have been investigated as a biomarker 
of heart function in pathological conditions, and this topic has been given increasing attention.         
 
1.3.1 Myosin light chains (MLCs) 
            Myosin is a large and complicated molecule which contains different types of 
subunits.  Most of myosin molecules are composed of two head domains, two neck domains 
and one tail domain.  The head domain is composed of myosin heavy chains, which is the 
motor protein of the thick filament.  Myosin heavy chain has the ATPase activity and triggers 
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the sliding between thick and thin filaments and the contraction.  The neck domain is 
composed of myosin light chains, which are myosin light chain 1 and myosin light chain 2 
(27-29). These myosin light chains play both structural and regulatory roles.  Myosin light 
chain 1 and myosin light chain 2 bind in the tandem to the domain of the myosin head that 
attaches to the myosin tail (30), stabilizing both the myosin head and the myosin tail.  Myosin 
light chain 1 is known as the essential light chain, which is present in the hinge of the myosin 
head for stability purpose.  Myosin light chain 2 is the regulatory light chain which performs 
the modulation in between the myosin head and myosin tail.  It has been shown that 
interaction between myosin light chain 1 and actin play an important role in the regulation of 
contraction (27, 31-39).  Myosin light chain 1 knockdown model shows a ~50% of reduction 
of contractility (33).  The regulatory light chain, myosin light chain 2 is also involved in the 
regulation of contraction.  It has been demonstrated that phosphorylation of myosin light 
chain 2 regulates Ca-dependent contraction (40-42).  Because of the presence of myosin light 
chains, the myosin structure maintains stable and the contraction process remains regular in 
the physiological condition, which indicates the normal function of the cardiac sarcomere.  
However, a different story is presented in the pathological condition.   
 
1.3.2 Myosin light chains in ischemia/reperfusion injury 
            The underlying molecular mechanism of ischemia/reperfusion injury still remains 
unclear.  Protein damage within the cardiomyocyte has been considered a key event during 
ischemia/reperfusion injury.  However, the main protein-protein interactions or substrate-
enzyme reactions in this pathological process are still poorly understood.  It is almost certain 
that ischemia/reperfusion injury is a complex process, which includes various factors, such as 
structural protein, energy metabolic proteins, kinase and proteolytic enzyme.  It has been 
shown that myosin light chains are one potential target for the protein degradation during 
ischemia/reperfusion.  Myosin light chain modification such as phosphorylation, modulates 
contractile force generation during ischemia/reperfusion (43).  The correlation between the 
function of the heart and the alteration in phosphorylation of myosin light chain has been 
reported (44-45).  In addition, some studies have demonstrated that both myosin light chain 1 
and myosin light chain 2 are released into the effluent of an ischemic heart (45), indicating 
that myosin light chains could be a target for the pathological heart.  However, no conclusion 
has been made on what proteolytic enzyme is responsible for the degradation of myosin light 
chains, and the molecular mechanism of the release of this degraded protein is still under 
investigation.  Our studies have shown that myosin light chains are degraded by matrix 
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metalloproteinase-2 (MMP-2) during I/R (22, 46-47), and protein kinases, such as myosin 
light chain kinase (MLCK) and Rho kinase, are partially involved in this process (48).  
Despite there are many unanswered questions about the molecular basis of I/R injury in the 
heart, myosin light chains has become one of the key biomarkers for heart injury.   
 
1.4 Kinase pathways 
 
            Kinase is a type of enzyme that catalyzes the phosphorylation of molecules, and the 
phosphorylation can change the molecules’ activity and ability to react with other molecules 
to perform different cellular responses. Therefore, kinases are crucial in metabolism, cell 
signaling, protein regulation and many other physiological functions.  Beside the vital role of 
kinases in the physiological condition, it has been widely shown that kinases also play an 
important role in pathological conditions.  There is a group of more than 500 protein kinases 
(49), which are an intricate part of ischemia/reperfusion.  These vascular and cellular events 
alter the response of many kinases, leading to subsequent cell injury and dysfunction.  Studies 
have reported that MLCK, protein kinase C (PKC) and Rho kinase, are at least, partially 
related to I/R injury (48).  The recognition that these kinases are involved in I/R will permit 
us to find better therapeutic methods to control these ubiquitous and highly recognizable 
important enzymes.   
 
Figure 1.1  
Proposed mechanism triggered by reactive oxygen species (ROS) that leads to cardiac contractile 
dysfunction. MLC1 – myosin light chain 1; MLCK – myosin light chain kinase; MLCP – myosin light 
chain phosphatase; MLC1-P – phosphorylated MLC; MMP-2 – matrix metalloproteinase-2 (use with 
permission) 
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1.4.1 Myosin light chain kinase (MLCK) pathway 
            Currently, the role of the myosin light chain kinase (MLCK) pathway in the 
development of cardiovascular disease and I/R injury has gained growing attention (50). 
MLCK, also known as MYLK, is a Ca2+/calmodulin activated serine/threonine-specific 
protein kinase that phosphorylates the regulatory light chain of myosin (51-52).  
Phosphorylation of cardiac myosin heavy chains and light chains by a kinase, such as 
MYLK3, potentiates the force and the rate of cross-bridge recruitment in cardiomyocytes 
(53).  The MLCK is activated by the extracellular-regulated kinase (54-55).  The MLCK 
pathway has been reported to be involved in the pathology of several cardiovascular disorders 
(56-57).  Studies have shown that, in response to I/R, MLCK activity is increased and this 
increase in activity is mainly associated with phosphorylation of MLC1, and inhibition of 
MLCK protects heart from I/R injury by regulation of phosphorylation of MLC (55, 58).  
These data suggest that inhibition of MLCK’s increased phosphorylation of MLC1 can be a 
valid, therapeutic target.  However, the knowledge of the effectors of the MLCK pathways is 
still limited, and the understanding of the molecular mechanism of MLCK pathway is 
fundamental for the therapeutic strategy development.   
 
1.4.2 Rho kinase pathway 
            Rho kinase (ROCK) is one of the major downstream mediators of the GTPase RhoA 
and plays an important role in the cytoskeleton (59).  It is involved in a wide range of crucial 
cellular functions, such as migration, contraction, proliferation, motility and adhesion (60).  
Moreover, ROCK regulates contractile force generation by phosphorylating several 
contractile proteins.  It has been well demonstrated that MLC is one of the targets for the 
phosphorylation by Rho kinase pathway (23).  When ROCK is activated by the active form of 
Rho, ROCK phosphorylates the myosin binding subunit of myosin phosphatase inhibiting its 
activity, and thus increases the phosphorylation of MLC of myosin II (61-63).  Evidence has 
shown that Rho kinase pathway plays a critical role in the pathogenesis of several 
cardiovascular disorders (64-66).  It is well established that the inhibition of ROCK protects 
I/R hearts from contractile dysfunction (67).  Our research lab has recently indicated that the 
mechanism of protection of I/R heart, in addition to inhibition of ROCK, may also up-
regulate energy metabolic protein such as lactate dehydrogenase (LDH) and glyceraldehyde-
3-phosphate dehydrogenase, which is involved in an increase of energy production (67), 
suggesting that kinase pathways in the I/R heart might also regulates metabolic process.   
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1.4.3 Protein kinase C (PCK) pathway 
            Protein kinase C (PKC) is a group of protein serine/threonine kinase that are related to 
the regulation of protein function via phosphorylation of the proteins. PKC has been 
classified as 1) the conventional PKCs, the diacyglycerol (DAG), calcium-dependent PKCs; 
2) the novel PKCs, which require DAG, but not calcium; 3) the atypical PKCs, which are not 
stimulated by DAG or calcium, but are stimulate by lipid-derived second messengers (68). 
PKCs are expressed in most of the tissues and play crucial role in many signal transduction 
cascades such as muscle contraction (69), platelet aggregation (70) and neuronal excitation 
(71). It has been shown that there are abundant expression of PKCs in human and rat 
cardiomyoscytes (72-74). Different isozymes of PKCs might have different effects in 
response to physiological and pathological conditions. For example, activation of δPKC and 
εPKC shows a protective effect in ischemic heart (75-77), in contrast, depletion of αPKC by 
gene knock –out increased myocardial contractility (78). Pharmacological tools have been 
developed to study the role of PKCs in the pathogenesis of heart injury. These include PKC 
activator and various PKC inhibitors. However, most of these agents are not selective for the 
individual PKC isozymes (79-82). In addition, most of the substrate or targets of PKCs have 
not yet been identified. It is important to identify the proper PKC isozymes and it targets to 
develop therapeutic strategies for the treatment of pathological cardiac diseases. 
             
1.4.4 Kinase inhibitor 
            Since it has been found that protein kinases play a significant role in the pathogenesis 
of cardiovascular disease including I/R injury, hypertension, coronary and vascular 
vasospasm (83-84), various protein kinases have been targeted for therapeutic potential.   
In recent years, several MLCK inhibitors have been reported, including K-252a (85), 
ML-7 (86), ML-9 (87) and peptide 18 (88). These MLCK inhibitors are newly developed 
small molecule inhibitors. Small molecule inhibitors allow researchers to have better 
condition to study multiple aspects of the molecule mechanisms, especially the signaling 
pathways within the cells. Among these reported inhibitors, ML-7 is one of the most widely 
used MLCK inhibitors.  ML-7 has been reported to be able to protect the heart in I/R injury 
(50, 89) and have beneficial effects in brain injury (90) and glaucoma (91).  Our studies have 
shown that the cardio protective effects of ML-7’s inhibition of MLCK in I/R injury are 
mainly associated with the protection of contractile function, via regulating the 
phosphorylation of myosin light chain 1 (MLC1), which in turn, regulate MLC1 degradation 
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by MMP-2.  This data suggests that the inhibition of MLCK (with ML-7, for example) 
represents a potential for new therapeutic strategies aiming to regulate MLC phosphorylation 
levels in the treatment of I/R injury. 
Other studies suggest that ROCK is a promising pharmacological target for I/R injury.  
Inhibition of ROCK has been shown to have cardio protective effect for the treatment of I/R 
injury and myocardial infarction (MI) (92-99).  Y-27632, it is one of the well-known ROCK 
inhibitors, has been reported to be able to reduce the I/R injury, infarct size in response to 
experimental myocardial infarction (MI) rat model (100).  Similar results have shown that 
administration of Y-27362 results in a more than 80% of functional recovery in the heart 
subjected to I/R in our research (23).  Additionally, potential targets for ROCK have been 
identified, which includes contractile proteins and metabolic proteins (23, 101). 
Protein kinase activation in the cardiovascular diseases induce cellular signaling 
pathways which have both a beneficial and harmful effect.  To date, neither the signaling 
pathways of protein kinases in pathological heart, nor the molecular mechanism of kinase 
inhibition treatment are fully investigated.  Thus, more studies are necessary for the 
understanding of protein kinases, and it is the fundamental stage for the development of 
therapeutic strategy. 
  
1.5 Matrix metalloproteinases (MMPs) 
 
               Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes involved in 
the degradation of protein in the matrix (102).  MMPs contain zinc ion in their active site, and 
zinc is indispensable for proper catalytic function (103).  It has been described that MMPs are 
involved in not only the physiological processes such as, platelet aggregation, wound healing 
(104), bone formation (105) and angiogenesis (106), but also in the pathological processes, 
such as rheumatoid arthritis (107), multiple sclerosis (108), tumor cell invasion (109), 
atherosclerosis, myocardial infarction, heart failure, ventricular remodeling and myocardial 
I/R injury (110-113).  To date, among all these MMPs, matrix metalloproteinase-2 (MMP-2) 
is probably one of the most widely studied types. 
 
1.5.1 Matrix metalloproteinase-2 (MMP-2) 
             MMP-2 is also known as type IV collagenase and gelatinase A, and it has been 
extensively described for its extracellular functions. However, a growing number of studies 
show that it also has important intracellular functions, mainly in pathological conditions (46, 
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89).  One of these intracellular functions is the negative effect of MMP-2 in cardiovascular 
disease.  MMP-2 has been reported to contribute to cardiac dysfunction by degrading 
intracellular contractile structural proteins, such as myosin light chain 1 (22), troponin I (114), 
titin (115) and alpha-actinin (116).  Under the normal physiological conditions, matrix 
metalloproteinase-2 activity is regulated at multiple levels.  MMP-2 is expressed as a pro-
enzyme.  Classical activation of MMP-2 involves proteolytic cleavage of the N-terminal 
propeptide by a membrane-type MMP.  Therefore, the key cysteine thiol residue with active 
zinc site can be exposed for binding.  Additionally, there is non-classical activation of MMP-
2, for example, MMP-2 can also be activated by the reactive oxygen/nitrogen species, such as 
peroxynitrite (47,46,117,118).  Another mechanism for the regulation of MMP-2 activity is 
the inhibition by tissue inhibitors of metalloproteinases (TIMPs) (103, 119).  Both activated 
and pro-MMP-2 can be inhibited by TIMPs, and TIMPs can inhibit the membrane-type MMP, 
and prevent the activation of the MMPs.  Besides, TIMPs can directly form a complex with 
the active MMPs and inhibit its activity (120).  In the heart, TIMP-4 is the major isoform 
expressed and inhibits MMP-2, preventing the cleavage of the propeptide domain of MMP-2 
and the consequent activation of MMP-2 (121).  Also, MMP-2 can be regulated by the gene 
transcription and translation or post-translational modification, such as gluathiolation and 
phosphorylation (119).  Moreover, active MMP-2 can be inhibited by many different 
pharmacological compounds against MMPs. 
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Figure 1.2 
Classification of human MMPs. Schematic representation of the structure of the 24 human matrix 
metalloproteinases (MMPs), which are classified into four different groups on the basis of domain 
organization. (Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the 
post-trial era. Nat Rev Cancer. 2002 Sep, use with permission) 
 
1.5.2 Matrix metalloproteinase in ischemia/reperfusion injury 
             I/R injury is comprised of a series of complicated processes, and these processes 
range from metabolic to morphological and contractile adaption in response to 
ischemia/reperfusion.  Studies have shown that MMP-2 contributes to acute cardiac 
dysfunction caused by I/R injury (47, 122).  One of the mechanisms by which MMP-2 gets 
involved in cardiac contractile dysfunction is the degradation of cardiac contractile proteins 
(22).  As mentioned above, contractile machinery proteins, such as myosin light chain 1, 
myosin light chain 2, troponin I and titin are important for normal cardiac muscle contraction.  
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The degradation of these important contractile proteins, by MMP-2, in response to conditions 
of increased oxidative stress, such as I/R, has been discussed previously.  Taking together the 
data suggests that the inhibition of the deleterious intracellular actions of MMP-2 can be an 
important therapeutic target for the prevention of oxidative stress induced cardiac contractile 
dysfunction.   
 
1.5.3 Matrix metalloproteinase inhibitors 
          Pharmacological approaches have been developed against MMPs for more than 30 
years.  MMP inhibitors, such as batimastat (123), marimastat (124) , ONO-4817 (115), PD-
166793 (125) and Ilomastat (126) have been frequently used in different experimental models 
of pathological conditions.  Among the many MMPs inhibitors that are commercially 
available, few are classically used in cardiovascular studies.  Among these inhibitors, 
phenanthroline and doxycycline have been shown to protect hearts from I/R injury (127) 
(128). 
Phenanthroline is a heterocyclic organic compound that exhibits chelating actions by 
forming stable complexes with most metal ions, including zinc, a metal ion present in the 
MMP active site.  It is this chelation of zinc that inhibits MMPs activity.  Studies on I/R 
injury have shown that using phenanthroline, as a MMP-2 inhibitor, can prevent the 
degradation and the release of proteins during reperfusion (122).  However, one of the main 
problems with the use of this compound is its toxicity, due to the fact that the chelation of 
metal ions is indiscriminate and can affect many other metalloproteins.  In addition, 
phenanthroline is also a broad spectra MMP inhibitor and not specific to MMP-2. 
The tetracycline class of antibiotics has been proven to be one of the most clinically 
useful tools in MMP inhibition, especially doxycycline.  Tetracyclines can inhibit MMPs’ 
activity through their ability to chelate the catalytic zinc essential for MMP activity (129).  
Doxycycline has been used in the experimental model of I/R injury to inhibit MMP-2 and has 
been shown to improve acute contractile dysfunction (122).  Based on the promising results 
from pre-clinical studies using doxycycline, several clinical studies are currently 
investigating the efficacy of doxycycline in post MI remodeling and doxycycline in cardio 
protection during, and following, the coronary artery bypass grafting(130). 
           It is known that MMP-2 have both extracellular and intracellular functions in 
pathological condition, and inhibition of MMPs is protective.  However, the physiological 
role of MMP-2 is also important.  Thus, the development of a selective MMP-2 inhibitor is 
crucial to understanding of the molecular mechanisms involved in regulating the 
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physiological and pathological roles of MMP-2.  Moreover, the understanding of how MMP-
2 actions contribute to both normal physiology and developing pathology is the key to the 
development of highly efficient therapies aiming at inhibition of MMP-2. 
 
1.6 Energy metabolic proteins 
 
           Cardiomyocyte is the basic functional cell unit in the cardiac tissue, and it is 
responsible for the contraction of the cardiac muscle.  One of the most important features of 
cardiomyocytes is the high density of mitochondria in the cytoplasm, allowing cardiomyocyte 
to produce ATP effectively, making them highly resistant to fatigue.  Mitochondrion is the 
factory where aerobic respiration transforms the biochemical energy form nutrients into ATP.  
Aerobic respiration is constituted of three metabolic processes, which are involved with a 
variety of metabolic proteins.  Most of these metabolic proteins are enzymes which perform 
different catalytic role through the whole ATP generating process.  During physiological 
conditions, cardiac tissue is abundant in oxygen, and aerobic respiration performs as usual 
and produces enough ATP for maintaining the normal function of the heart.  However, under 
pathological conditions, such as I/R, lack of oxygen and nutrients leads to the disorder of 
energy production.  Alteration and modulation of metabolic processes and metabolic proteins 
will occur and complicate this pathological event.  Studies focusing on the metabolic protein 
in the I/R heart have been reported since 1980s (131-132).  However, the underlying 
mechanism in which the energy metabolic proteins contribute to the development of 
myocardial I/R injury is still unclear.  More studies are needed for the understanding of the 
pathogenesis of myocardial I/R injury regarding to metabolic process. 
 
1.6.1 Glycolysis and citric acid cycle 
            Glycolysis and citric acid cycle are the first two steps of aerobic respiration.  Neither 
of them requires oxygen, but they act differently in aerobic and anaerobic conditions.  
Glycolysis is a sequence of biochemical reactions that converts glucose into pyruvate with 
the concomitant production of a relatively small amount of ATP.  Glycolysis is an especially 
important pathway for organisms that ferment sugars.  Glycolysis also serves as a source of 
raw materials for the synthesis of other compounds.  After glycolysis, pyruvate is oxidized to 
acetyl-CoA, and enters the citric acid cycle.  Citric acid cycle is also known as the 
tricarboxylic acid cycle, or the Krebs cycle (133).  Citric acid cycle is a series of biochemical 
reactions involving different enzymes and co-enzymes, and oxidizes acetyl-CoA to form 
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high-energy reactive molecules, NADH and FADH, which will be used in the electron 
transport chain to produce ATP.  However, when there is not enough oxygen, the citric acid 
cycle will not occur, and pyruvate will be fermented into lactic acid.  This process is known 
as anaerobic glycolysis, which has been considered as one of the important energy source for 
the ischemic heart.  
 
1.6.2 Electron transport chain 
            Electron transport chain is also known as respiratory chain and oxidative 
phosphorylation.  It is the last and the most important step of the aerobic respiration.  This 
metabolic pathway takes place in the mitochondria and uses its special structure, enzymes 
and the high-energy reactive molecules released from the oxidation of pyruvate to produce 
ATP.  This whole process is carried out by a set of complexes including NADH 
dehydrogenase (complex I), succinate dehydrogenase (complex II), cytochrome bc1 
complaex (complex III), cytochrome c oxidase (complex IV). These complexes transport 
electrons from electron donors to electron acceptors through redox reaction, and couple the 
electron with protons (H+) across the mitochondria inner membrane.  The protons accumulate 
in the mitochondrial intermembrane matrix and generate an electrochemical proton gradient, 
which can perform ATP synthesis via the ATP synthase (complex V), within the electron 
transport chain.   There are five large molecules complex composing the electron transport 
chain.  During aerobic condition, these complexes transfer the electrons to the final electron 
acceptor oxygen and produce ATP, via ATP synthase, using the proton gradient, and thus 
supplying most of the physiological demands.  However, when oxygen is absent, the electron 
transport chain cannot perform its normal function.  In contrast, complex located in the 
mitochondrial membrane generates reactive oxygen species (15) during anaerobic condition 
and cause mitochondria fragmentation, which would eventually lead to cell death.  This 
process has been claimed to play a crucial role in the I/R injury (134). 
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Figure 1.3  
A diagram of cellular respiration including glycolysis, Krebs cycle (AKA citric acid cycle), and the 
electron transport chain (RegisFrey March 2007 Creative Commons CC Attribution-ShareAlike BY-SA 
3.0, use with permission) 
 
1.6.3 Energy metabolic pathways in ischemia/reperfusion injury 
            It has been suggested that electron transport chain is interrupted in anaerobic 
condition.  Interruption of electron transport chain causes an increasing production of ROS, 
and ROS further activates harmful proteolytic enzyme and kinases, which contribute to the 
damage and eventually leads to mitochondrial fragmentation and cell death (135).  During 
reperfusion, ROS generation also enhances, due to the suddenly increased oxygen 
concentration (11).  One of the important proteolytic enzymes has been identified, which is 
matrix metalloproteinase-2 (MMP-2).  It has been shown that ROS activates MMP-2, and 
MMP-2 contributes to the development of ventricle remodeling and other pathological 
process in the heart (136).  On the other hand, mitochondrial antioxidants are overexpressed, 
preventing the mitochondrial damage from ROS and improving the cardiac tolerance from 
I/R (137-138).  Therefore, these pathways suggest that mitochondria play a significant role in 
the pathological process during I/R, and acts like a double-edged sword.  In addition, during 
anaerobic condition, for example, in ischemia, lactic acid glycolysis is the major resource for 
the energy production, since citric acid cycle and oxidative phosphorylation cannot occur.  It 
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has been reported in our study that during I/R, two important enzyme in lactic acid glycolysis, 
lactate dehydrogenase (LDH) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), are 
up-regulated, which provides the heart with a supplemental energy generation (23). Moreover, 
another process of energy production, citric acid cycle, has rarely been focused.  Even though 
citric acid cycle does not require oxygen, pyruvate will not be oxidized to acetyl-CoA and 
enter the citric acid cycle.  During I/R, the role of citric acid cycle is still unclear.  Some 
suggest that it could be an important ATP source (139) and others claim that it may contribute 
to ROS generation (140).  It is intricate how the energy metabolic pathways are modulated in 
the pathological process during I/R, and the understanding of these molecular mechanisms is 
crucial for the development of innovative treatments for cardiovascular diseases.   
 
1.7 Proteomic approach 
 
              “PROTEOME” was introduced in 1994, and has been given great attention for two 
decades. As we know that proteins are the basic functional unit in the cells and the most 
common diagnostic and therapeutic targets in medicine. The search of proteome can discover 
new diagnostic and therapeutic targets, which leads to the development of new strategies for 
diagnosis and treatments. Proteome is the protein expression profile of cells, tissues or the 
intact organs under a certain condition, such as normal physiological condition, pathological 
condition and experimental condition.  Proteomics is the dynamic changes of the protein 
expression profile under these different conditions.  Proteomics approach is one of the most 
common methods to search and discover the new diagnostic and therapeutic target for 
different diseases.  The use of proteomics to study cardiovascular diseases has allowed the 
characterization of global alterations in comparative protein expression and identifies the 
biomarkers and the treatment target for its pathogenesis.  Two-dimensional electrophoresis 
(2-DE) and mass spectrometry (MS) are the most fundamental techniques in proteomics 
research.  In most of the cases, the individual proteins and their fragments or modifed forms 
are separated by their isoelectric point and molecular weight using 2-DE. After 2-DE, 
quantitative analysis of protein spots intensity from 2-DE was measured which are then 
further identified and analyzed by MS.  Proteomic methodology has been developing with the 
improvement of bioinformatics methods to correlate enzymatic digest mass fingerprints and 
peptide fragmentation data arising from mass spectrometry analysis with genome sequence.  
The combination of physical protein data from MS with genome data has made unambiguous 
identification of proteins from 2-DE gels much more rapid and much cheaper than 
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conventional peptide sequencing (141).  Many proteome studies have been done for the 
comparative protein expression among different physiological and pathological conditions in 
the heart, and more than 50 proteins in heart diseases have been identified.  Studies suggest 
that these proteins are important in the regulation of the heart function (142-143).  To date, 
more proteomic research focusing on the cardiovascular diseases are still under operation all 
over the world, and hence it can be predicted that more data will be generated in the 
upcoming future. 
 
 
 
Figure 1.4  
A proteomic workflow diagram, showing sample separation by gel matrix, protein digestion, mass 
analysis by a mass spectrometer, validated search analysis, and protein identification. (Vincent Shen, 
Mistaken identities in proteomics, Biotechniques 2011January, use with permission) 
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1.8 Hypothesis 
 
 It is established that MMP-2 is activated and degrades contractile proteins during I/R, 
and many other factors including metabolic enzymes, protein kinases and structural proteins 
are affected by I/R.  However, the molecular mechanisms responsible for these changes are 
still not clear.  Since MMP-2 is known for its broad spectrum of action, I hypothesize that, in 
addition to contractile proteins, proteins related to regulation of energy metabolism are MMP-
2 targets during I/R, and protein kinase such as myosin light chain kinase (MLCK) is also 
involved in this process. The use of proteomics in studying heart injury triggered by I/R will 
reveal new potential targets for pharmacological protection of heart from I/R induced 
contractile dysfunction. In addition, selective inhibition of MMP-2 using MMP-2 siRNA will 
protect the heart from I/R injury. 
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1.9 Objectives 
 
            My PhD project had five main objectives: 
1. To identify proteomic profile in the heart subjected to I/R injury  
2. To compare the proteomic profile in right and left ventricles from the heart subjected 
to ischemia/reperfusion injury  
3. To determine the effect of the Myosin Light Chain Kinase inhibitor ML-7 on the 
proteome of hearts subjected to I/R injury 
4. To analyze the inhibition of MMP-2 gene expression with small interfering RNA in 
isolated cardiomyocytes by proteomic analysis, with the focus on the degradation of 
energy metabolic proteins by MMP-2 
5. To determine the cardioprotective effect of inhibition of MMP-2 using MMP-2 siRNA 
on isolated cardiomyocytes. 
 
           The underlying mechanism of I/R-induced heart contractile dysfunction is still unclear.  
Many factors have been shown to contribute to the development in the I/R injury.  Using 
proteomics approaches provide a wide range and comprehensive profiles of the dynamic 
alteration of the proteins.  This will give the investigators evidence, links and clues to 
integrate the mechanism.  From the wide range of the protein profile, we have mainly focused 
on the energy metabolic proteins in this study.  It has been demonstrated that energy 
metabolic proteins are involved in the development of I/R injury, however, the underlying 
molecular mechanisms of the modulation of those proteins, especially the pathways of 
protein-protein interaction among energy metabolic proteins, kinases and proteolytic enzymes, 
are still poorly understood.   We considered that the study of changes in proteomic profile of 
energy metabolic proteins may be a key to reveal the pathological mechanisms of I/R injury.  
The protection of the heart from degradation of contractile proteins by inhibition of myosin 
light chain kinase using pharmacological compound ML-7 has been shown in our studies.  
However, we do not know whether energy metabolic proteins are related to the myosin light 
chain kinase pathway, or if they are protected by ML-7 during I/R. In this study, we 
investigated the effect of myosin light chain kinase inhibitor ML-7 on the proteome of heart 
subjected to I/R injury.  We have also shown that the inhibition of MMP-2 protects the heart 
from I/R injury.  So far, we have only revealed that MMP-2 degrades contractile proteins, but 
no one knows whether MMP-2 degrades energy metabolic proteins.  In the other words, no 
one knows whether inhibition of MMP-2 would affect the energy metabolic proteins.  We 
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started to study the proteomics of inhibition of MMP-2 in cardiomyocyte.  The major propose 
of this study is to conceive a basic frame of the regulatory pathways of energy metabolic 
enzyme during I/R, in order to develop novel therapeutic strategies aimed at energy 
production during I/R.  
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2.1 Preface 
The manuscript presented here has been published in the journal Proteomics (Cadete 
and Lin et al.2012). This manuscript addressed objectives 1 and 2 of my PhD project. 
1. To identify proteomic profile in the heart subjected to I/R injury  
2. To compare the proteomic profile in right and left ventricle from heart subjected to 
ischemia/reperfusion injury  
 
         This manuscript is the first approach of the project. We demonstrated the proteomic 
profile of the I/R heart from a completely different angle, namely we evaluated proteomic 
alteration in different regions of the heart. Since the studies of right ventricle have been 
overshadowed by numerous studies of left ventricle and the right ventricle is often neglected 
on cardiac research, in this study, we compared for the first time the proteomic alteration in 
right and left ventricle from heart subjected to I/R injury. Our finding determined for the first 
time that there are different protein expressions between left and right ventricles response to 
I/R injury. In addition, results show that there are many energy metabolic proteins affected in 
I/R injury. This finding gave us some new ideas of the mechanism of I/R injury, namely not 
only are contractile proteins effected in I/R, but also energy metabolic proteins are involve in 
I/R injury. This study provided the research foundation for pursuing the underlying molecular 
mechanism of energy metabolic proteins regulation in I/R injury. 
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2.2 Abstract 
 
Ischemia/reperfusion (I/R) injury is a major consequence of cardiovascular 
interventions. The study of changes of the left and right ventricle proteomes from hearts 
subjected to I/R may be key to revealing the pathological mechanisms underlying I/R-
induced heart contractile dysfunction.  
Isolated rat hearts were perfused under aerobic conditions or subjected to 25 min 
global ischemia and 30 min reperfusion. At the end of perfusion right and left ventricular 
homogenates were analyzed by 2-dimensional electrophoresis (2-DE). 
Contractile function and coronary flow were significantly reduced by I/R. 2-DE 
followed by mass spectrometry identified 10 protein spots whose levels were significantly 
different between aerobic left and right ventricles, 8 protein spots whose levels were different 
between aerobic and I/R left ventricle, 10 protein spots whose levels were different between 
aerobic and I/R right ventricle 10 protein spots whose levels were different between the I/R 
groups. Among these protein spots were ATP synthase β subunit, myosin light chain 2, 
myosin heavy chain fragments, peroxiredoxin-2 and heat shock proteins, previously 
associated with cardiovascular disease.  
These results reveal differences between proteomes of left and right ventricle both 
under aerobic conditions and in response to I/R which contribute to a better understanding of 
I/R injury. 
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2.3 Introduction 
 
           The heart can be viewed as two independent pumps, the one delivering blood to the 
lungs, the other to the rest of the body. The right heart, containing right atrium and ventricle, 
pumps blood through the pulmonary circulation. The left heart comprised of the left atrium 
and ventricle and pumps blood through the systemic circulation. Because the contractile work 
performed by each side of the heart is different the anatomy of right and left ventricles (the 
most important functional parts of the heart) is also different. The left ventricular wall is 
thicker than the right due to the fact that resistance and pressures are higher in the systemic 
branch of the circulatory system, in comparison to the pulmonary circulation. Although the 
knowledge and understanding of cardiac anatomy and function is abundant, very little is 
known about differences in protein profiling and protein levels between different regions of 
the heart, including ventricles. Differences have been shown in protein expression levels 
between left and right ventricles in physiological conditions (144), but nothing is known 
about differences in protein expression levels between right and left ventricle from injured 
heart. Few studies have shown changes in cardiac protein expression but are limited to 
analysis of left ventricle (46, 145) or mitochondria (146). 
         Acute or chronic reduction in oxygen supply and/or nutrients can lead to severe, 
irreversible damage to the cardiac tissue and seriously impact cardiac contractile function. 
Studies of protein levels in myocardial tissue exhibiting contractile dysfunction have shown 
changes in protein expression in different regions of the heart that can be dependent on 
protein degradation, or changed expression of protein levels due to protein synthesis or 
release from the cell (147). Studies have shown that during ischemia, significant protein 
degradation is associated with contractile dysfunction (22, 46-47, 145). The study of the 
proteomes of the damaged heart due to ischemia/reperfusion (I/R) injury is key to a better 
understanding of the pathogenic mechanisms underlying I/R-induced contractile dysfunction. 
        The development of I/R injury, such as occurs in myocardial infarction (MI), has been 
attributed to several factors. Many of these factors have been identified either by using whole 
heart homogenates or left ventricle samples. The structural consequences of MI in adults are 
mostly dictated by left ventricular remodeling, leading to heart failure (148). Failure of 
proper oxygen delivery caused by a decrease in blood flow together with increased oxygen 
demand by the heart results in tissue ischemia. Severe ischemia can cause the cardiac muscle 
to die due to prolonged hypoxia, such as during MI.  
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Functional studies of the right ventricle have been overshadowed by studies of left ventricle 
function and the right ventricle is often ignored on cardiovascular studies. The role of the 
right ventricle was later recognized in certain conditions, such as in the follow-up of some 
corrected and non-corrected congenital heart diseases, in valvular heart diseases, in acute and 
chronic coronary arterial diseases, in pulmonary hypertension and in congestive heart failure 
(149).  
        Since different cardiac pathologies resulting in ischemia affect different regions of the 
heart, it is important to understand the molecular mechanisms by which different regions of 
the heart respond to ischemia. In this project, we focused on comparative studies of 
proteomes of left and right ventricles in physiological (aerobic perfusion) and pathological 
(I/R) conditions. Here we show that the right and left ventricles exhibit different aerobic 
proteomes. Moreover, when subjected to ischemia, the proteomic response of the right and 
left ventricles is also different. 
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2.4 Materials and Methods 
 
           The experimental procedures described below conform to the Guide to the Care and 
Use of Experimental Animals published by the Canadian Council on Animal Care. 
 
2.4.1 Isolated heart perfusions 
          Male Sprague-Dawley rats were anesthetized with sodium pentobarbital (40 mg/kg, 
i.p.). The hearts were rapidly excised and briefly rinsed by immersion in ice-cold Krebs-
Henseleit buffer. Spontaneously beating hearts were placed in a water-jacketed chamber 
(EMKA Technologies) to maintain their temperature at 37°C. Hearts were perfused in the 
Langendorff mode at a constant pressure of 60 mm Hg with modified Krebs-Henseleit buffer 
at 37ºC containing (in mM): NaCl (118), KCl (4.7), KH2PO4 (1.2), MgSO4  (1.2), CaCl2  
(3.0), NaHCO3  (25), glucose (11), and EDTA (0.5), and gassed continuously with 95% 
O2/5% CO2 (pH 7.4). 
 
2.4.2 Ischemia/reperfusion protocol 
           Control hearts (aerobic control, n=5 were perfused aerobically for 45 minutes. 
Ischemic hearts (I/R, n=4) after 25 min at aerobic perfusion were subjected to 20 minutes 
global no- flow ischemia by closing of aorta inflow line, followed by 30 min reperfusion. At 
the end of the perfusion protocol ventricular free wall biopsies from right and left ventricles 
were isolated and quickly snap frozen in liquid nitrogen and kept at -80˚ C until further 
analysis was perform. 
 
2.4.3 Preparation of heart protein extracts 
           Protein samples for 2-dimensional electrophoresis (2DE) were prepared at room 
temperature by mixing frozen (-80°C), powdered heart tissue (40 to 60mg wet weight) with 
200 µL rehydration buffer (8 mol/L urea, 4% CHAPS, 10 mmol/L DTT, 0.2% Bio-Lytes 3/10 
[BioRad]) at room temperature. Samples were sonicated twice for 5 seconds and centrifuged 
for 10 minutes at 10,000g to remove any insoluble particles. Protein content of the heart 
extract in rehydration buffer was measured with the BioRad protein assay.  
 
2.4.4 Two-Dimensional electrophoresis (2-DE) 
            Because we could not analyze more than 12 samples in 2DE setting (see explanation 
below) for analysis of ventricle proteomes we used 3 ventricular samples (n=3) for each of 
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the 4 groups.  
            Protein (0.4 mg) from ventricular samples (n=3/group) was applied to each of 11 cm 
immobilized linear pH gradient (5 to 8) strips (IPG, BioRad), with rehydration for 16–18 h at 
20ºC.  For isoelectrofocusing (IEF), the BioRad Protean IEF cell was used with the following 
conditions at 20ºC with fast voltage ramping: step 1: 15 min with end voltage at 250 V; step 2: 
150 min with end voltage at 8000 V; step 3: 35 000 V-hours (approximately 260 min).  After 
IEF, the strips were equilibrated according to the manufacturer’s instructions.  Second 
dimension of 2-DE was then carried out with Criterion pre-cast gels (8 – 16%) (BioRad).  
After separation, proteins were detected with Coomassie Briliant Blue R250 (BioRad). To 
minimize variations in resolving proteins during the 2-DE run, 12 gels were run 
simultaneously using a Criterion Dodeca Cell (BioRad). Because of this limitation for 2-DE 
analysis we used 3 hearts from each group. All the gels were stained in the same bath and 
next scanned with calibrated densitometer GS-800 (BioRad). Quantitative analysis of protein 
spots intensity from 2-DE was measured with PDQuest 7.1 measurement software (BioRad). 
The protein spot sensitivity threshold used to determine significant changes in protein spot 
size and density is based on 4 parameters: minimum peak value sensitivity, smallest spot area, 
largest spot area, and a noise filter level. Using these criteria for protein resolution and 
staining, we are able to obtain high reproducibility to analyze both a single protein from the 
same sample run in different gels (150) and a specific protein from different heart samples 
(22). Only protein spots with relative intensity between 2 and 500 arbitrary units were 
considered for analysis. 
 
2.4.5 Mass Spectrometry (MS) 
            Protein spots of interest were manually excised from the 2-DE gel.  These spots were 
then processed using a MassPrep Station from Micromass using the methods supplied by the 
manufacturer. Briefly, the excised gel fragment containing the protein spot was first destained 
in 200 µl of 50% acetonitrile with 50 mM ammonium bicarbonate at 37°C for 30 minutes, 
reduced, alkylated, digested with trypsin and extracted overnight at room temperature with 50 
µL of a mixture of formic acid, water, and isopropanol (1:3:2, vol:vol). The resulting tryptic 
digests were then analyzed by mass spectrometry (MS). For electrospray, quadruple time-of-
flight (Q-TOF) analysis, 1 µl of the solution was used. Liquid chromatography/mass 
spectrometry (LC/MS) was performed on a CapLC high-performance liquid chromatography 
unit (151) coupled with Q-TOF-2 mass spectrometer (Micromass).  A mass deviation of 0.2 
was tolerated and one missed cleavage site was allowed.  Resulting values from mass 
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spectrometry (MS/MS) analysis were used to search against the NCBInr and SwissProt 
databases with Mammalia specified.  We used the Mascot (www.matrixscience.com) search 
engine to search the protein database. 
 
2.4.6 Immunoblot analysis 
            Frozen heart tissue powder was homogenized on ice in 150 mM NaCl, 50 mmol/L 
Tris-HCl (pH 7.4) containing protease inhibitor cocktail (Sigma, St Louis, MO, USA) and 
0.1% Triton X-100. Homogenates were centrifuged at 10 000g at 4°C for 10 minutes, and the 
supernatant was collected and stored at -80°C until use. 
            Protein extracts from the same hearts used for 2DE (30 µg protein) from each of the 
groups were separated by SDS-PAGE (n=3/group). After electrophoresis proteins were 
transferred to a PVDF (polyvinylidene difluoride) membrane (BioRad). Membranes were 
probed with rabbit polyclonal anti-peroxiredoxin II (Santa Cruz Biotechnology), rabbit 
polyclonal anti-MLC2 (AbCam), rabbit polyclonal anti-enoyl-CoA hydratase (Santa Cruz 
Biotechnology), mouse monoclonal anti-heat shock protein-70 (Santa Cruz Biotechnology) 
according to the supplier’s instructions. Goat anti-rabbit and goat anti-mouse secondary 
antibodies, tagged with Alexa Fluor647 and Alexa fluor488 respectively (Invitrogen), were 
used and membranes developed with VersaDoc5000 using appropriate filters. Band densities 
were determined with Quantity One software (BioRad). 
 
2.4.7 Statistical Analysis 
            The protein spot levels were analyzed using PDQuest measurement software and 
evaluated by Kruskal Wallis and Mann-Whitney U test.  The proteins of interest were also 
analyzed with unpaired t-test followed by identification by mass spectrometry.  ANOVA or 
Kruskal-Wallis test was used in functional studies. Data are expressed as mean±SEM. 
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2.5 Results 
 
2.5.1 Cardiac function 
            Contractile function and coronary flow were used as a measurement of cardiac 
function. Contractile function is shown as rate pressure product (product between left 
ventricle developed pressure and heart rate) – RPP. Hearts subjected to 25 min of global, no-
flow ischemia followed by 30 min of reperfusion showed a nearly zero recovery of 
contractility during reperfusion in comparison to time-matched, aerobically perfused hearts 
(Figure 2.1, top). Also, coronary flow was significantly reduced (approximately 75 %) during 
reperfusion (Figure 2.1, bottom).  
 
Figure 2.1  
Mechanical function of rat hearts perfused aerobically or subjected to 25 min of global, no-flow 
ischemia followed by 30 min reperfusion.  Contractile function was assessed as RPP (rate pressure 
product) and calculated as the product of left ventricular developed pressure by heart rate (top panel).  
Coronary flow (bottom panel) was evaluated by measurement of Krebs-Henseleit buffer flow through 
coronary arteries in milliliters per minute.  n= 4/5.* p<0.05 vs.  Aerobic controls 
 
2.5.2 Right and left ventricle proteomes from aerobic hearts 
            In order to determine changes in protein abundance in left and right ventricles of the 
heart and the effect of ischemia on the heart tissue, we have compared the 2-D 
electrophorograms of left ventricular and right ventricular myocardial tissue samples from 
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aerobic and ischemic tissues. Representative 2-D electrophorograms from each analyzed 
group are shown in figure 2.2.  
 
Figure 2.2  
Two-dimensional electrophoresis (2-DE).  Representative 2-DE gels from each of the analyzed groups.  
Protein spots found to be significantly changed between groups are indicated with arrows and the 
respective protein spot number. 
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           Comparison of the 2D gels from right and left ventricles revealed significant 
differences between the analyzed proteomes. The protein identity, accuracy of protein 
identification and number of matched peptides are summarized in tables 2.1-2.3. Proteins 
whose levels showed statistically significant differences in between left and right ventricles 
(aerobic or I/R) or between aerobic and ischemic heart tissues were included in the tables.  
For better visual presentation the altered proteins are grouped in 3 groups according to their 
abundance; 2-20, 20-80 and 80-500 arbitrary units (Fig. 2.3-2.6).  Analysis of right and left 
ventricle proteomes from aerobically perfused hearts revealed 10 proteins showing different 
protein levels (Fig. 2.3). Of the 10 protein spots 9 proteins were identified by mass 
spectrometry. Structural proteins (vimentin, cardiac myosin light chain 2) and unknown 
protein (the 10th protein) showed higher level in left ventricle. Also, the levels of proteins 
involved in energy metabolism (mitochondrial F1-APTase β subunit, isovaleryl-CoA 
dehydrogenase and chain a, 2-enoyl-CoA hydratase) were higher in left ventricle in 
comparison to right ventricle. In contrast, the level of other proteins also involved in energy 
metabolism, such as subunits of enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase, 
cytochrome b-c1 complex and of ATP synthase, were higher in right ventricle. In addition 
peroxiredoxin 3, an antioxidant protein, was identified and its level was higher in the right 
ventricle (Fig. 2.3). 
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Table 2.1 Identification of protein spots from aerobic left ventricle and aerobic right ventricle 
heart homogenates – differences in protein profile between left and right ventricle perfused 
under aerobic conditions. 
Protein spot 
NO. 
Fold 
change 
Mowse 
score
ａ) 
Queries 
matched 
Sequence 
coverage 
(%) 
pI/MW(kDa) Identified protein 
Energy 
metabolism 
      
127 ↓b) -1.8 310 5 8% 9.11/83.20 
 
mitochondrial long-
chain enoyl-CoA 
hydratase/3-
hydroxycyl-CoA 
dehydrogenase α-
subunit 
125 ↑ 2 108 4 6% 8.03/48.86 isovaleryl-CoA 
dehydrogenase, 
mitochondrial 
precursor 
128 ↑ 2.9 398 7 31% 5.07/38.74  F1-ATPase β 
subunit 
130 ↑ 1.3 373 7 31% 6.41/28.55 chain A, 2-enoyl-
CoA hydratase 
132 ↓ -1.4 474 7 14% 5.57/53.50 cytochrome b-c1 
complex subunit 1, 
mitochondrial 
precursor 
134 ↓ -1.3 117 2 11% 6.17/18.81  
 
ATP synthase 
subunit d, 
mitochondrial 
Structural 
proteins 
      
119 ↑ 1.9 704 13 31% 5.06/53.76 vimentin 
135 ↑ 1.2 891 8 42% 4.86/18.88 myosin light chain 2                              
137 ↑ 3.3 162  3 25% 5.48/20.90 unknown protein 
Others       
133 ↓ -1.6 494 6 24% 7.14/28.57  peroxiredoxin 3 
a) Ions score is -10*Log(P), where P is the probability that the observed match is a random 
event.   
Individual ions scores > 37 indicate identity or extensive homology (p<0.05). 
b) The arrows (↑↓) indicate statistically significant changes in protein levels (versus aerobic 
right ventricle) 
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Figure 2.3  
Comparison right and left ventricle proteomes from aerobic hearts.  For better visual presentation the 
altered proteins are grouped in 3 groups.  Each panel represents one protein group according to the 
level of abundance.   n=3/group * p<0.05 vs. aerobic right ventricle. 
 
2.5.3 Effect of I/R on protein profile in left ventricle 
            Ischemia induced several changes in protein levels in left ventricle (Fig. 2.4). Eight 
proteins were altered by I/R. The levels of structural proteins involved in contractile function, 
such as two isoforms of α-actin and myosin heavy chain 5, as well as dnaK-type molecular 
chaperone hsp72-ps 1 (also known as a heat shock protein 70) were elevated. In contrast heat 
shock protein β-6, myosin light chain 2, β subunit of F1-ATPase and an unknown protein 
were significantly reduced in response to ischemia (Fig. 2.4).  
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Figure 2.4 
Effect of ischemia/reperfusion on ventricle proteomes.  For better visual presentation the altered 
proteins are grouped in 3 groups.  Each panel represents one protein group according to the level of 
abundance.  n=3 * p<0.05 vs.  Aerobic left ventricle 
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Table 2.2 Identification of protein spots from aerobic left ventricle and ischemic left ventricle 
heart homogenates – Effect of ischemia on protein profile in left ventricle. 
Protein spot 
NO. 
 
Fold 
change 
Mowse 
score
ａ) 
Queries 
matched 
Sequence 
coverage 
(%) 
pI/MW(kDa) Identified 
protein 
Energy 
Metabolism 
      
128 ↓ -1.9 398 7 31% 5.07/38.74 F1-ATPase β 
subunit 
Structural 
proteins 
      
122 ↑ 1.8 751 12 34% 5.23/42.33 
 
actin, α cardiac 
muscle 1 
proprotein 
123 ↑ 3.1 792 11 36% 5.23/42.33 
 
actin, α cardiac 
muscle 1 
proprotein 
135 ↓ -1.2 891 8 42% 4.86/18.88 myosin light 
chain 2 
124 ↑ 1.7 328 7 16% 5.52/47.88  
 
cardiac myosin 
heavy chain 5 
Others       
121 ↑ 2.7 468 8 13% 
 
5.43/71.11 
 
heat shock 
protein 70 
136 ↓ -1.7 415 6 32% 
 
6.05/17.55  heat shock 
protein β-6                                   
a) Ions score is -10*Log (P), where P is the probability that the observed match is a random 
event.  
Individual ions scores > 37 indicate identity or extensive homology (p<0.05). 
b) The arrows (↑↓) indicate statistically significant changes in protein levels (versus aerobic 
left ventricle) 
 
 
2.5.4 Effect of I/R on protein profile in right ventricle 
            Ischemia resulted in alteration of 10 protein levels (Fig. 2.5). Of 5 proteins whose 
levels were increased, two are involved in fatty acid metabolism namely isovaleryl-CoA 
dehydrogenase and enoyl-CoA hydratase. In contrast the levels of subunit d of ATP synthase 
were decreased. The other 3 proteins whose levels were increased are: heat shock proteins 70 
and β-1 and the antioxidant protein peroxiredoxin-2.  
           The 5 proteins whose levels were decreased include 2 enzymes involved in energy 
metabolism (B chain of L-lactate dehydrogenase and subunit 1 of cytochrome b-c1 
complex,precursor). The levels of heat shock protein β-6 and histidine triad nucleotide-
binding protein 1 were also reduced (Fig. 2.5). 
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Figure 2.5 
Effect of ischemia/reperfusion on protein profile in right ventricle.  For better visual presentation the 
altered proteins are grouped in 2 groups.  Each panel represents one protein group according to the 
level of abundance.n=3 * p<0.05 vs.  Aerobic right ventricle 
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Table 2.3 Identification of protein spots from aerobic and ischemic right ventricle heart 
homogenates – Effect of ischemia on the protein profile in right ventricle. 
Protein spot 
NO. 
Fold 
change 
Mowse 
score
ａ) 
Queries 
matched 
Sequence 
coverage 
(%) 
pI/MW(kDa) Identified protein 
Energy 
metabolism 
      
125 ↑b) 1.9 108 4 6% 8.03/48.86 
 
isovaleryl-CoA 
dehydrogenase, 
mitochondrial 
precursor 
126 ↓ -1.6 768 14 46% 5.70/36.87 L-lactate 
dehydrogenase B 
chain 
130 ↑ 2.2 373 7 31% 6.41/28.55  chain A, 2-Enoyl-
Coa hydratase 
132 ↓ -1.2 474 7 14% 5.57/53.50 cytochrome b-c1 
complex subunit 1, 
mitochondrial 
precursor 
134 ↓ -1.2 117 2 11% 6.17/18.81 ATP synthase 
subunit d, 
mitochondrial 
Other       
121 ↑ 1.4 468 8 13% 5.43/71.11 heat shock protein 
70 
129 ↑ 1.4 589 9 42% 6.12/22.94 heat shock protein 
beta-1 
131 ↑ 1.5 573 7 31% 5.34/21.91 peroxiredoxin 2  
136 ↓ -1.4 415 6 32% 
 
6.05/17.55  heat shock protein 
beta-6                                   
138 ↓ -2.2 180 4 42% 6.36/13.88  histidine triad 
nucleotide-binding 
protein 1               
 
a) Ions score is -10*Log (P), where P is the probability that the observed match is a random 
event.  Individual ions scores > 37 indicate identity or extensive homology (p<0.05). 
b) The arrows (↑↓) indicate statistically significant changes in protein levels (versus aerobic 
right ventricle) 
 
 
2.5.5 Right and left ventricle proteomes from I/R hearts  
            Comparison of the 2D gels of samples from right and left ventricles of I/R hearts 
revealed 8 proteins spots which were significantly different. Levels of 5 proteins were 
decreased (Fig. 2.6) and these proteins were identified as: α actin, heat shock proteins β-1 and 
β-6, proxiredoxin 2 and chain a of 2-enoyl-CoA hydratase. The group of proteins that 
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revealed an increase in their levels includes: myosin heavy chain 5, heat shock protein 70 and 
vimentin (Fig. 2.6). 
 
Figure 2.6 
Changes in right and left ventricle proteomes from hearts subjected to ischemia reperfusion.  For 
better visual presentation the altered proteins are grouped in 3 groups.  Each panel represents one 
protein group according to the level of abundance.  n=3/group * p<0.05 vs.  I/R right ventricle  
 
2.5.6 Validation of 2DE results 
            Protein level changes observed from 2DE for some proteins, was verified by 
immunoblotting (according to commercial availability) (Fig. 2.7). Myosin light chain 2 
(MLC2) and 2-enoyl-CoA hydratase were identified as significantly increased in the left 
ventricle, in comparison to the right, by 2DE. Immunoblotting analysis confirmed the 
observations made by 2DE (Fig. 2.7A). Similarly, the observed decrease of peroxiredoxin II 
level in right ventricles from I/R hearts in comparison to left ventricles of I/R heart (by 2DE) 
was confirmed by immunoblot analysis (Fig. 2.7B). To validate the 2DE results from aerobic 
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and I/R left ventricular samples, we measured MLC2 protein levels by immunoblotting (Fig. 
2.7C). Although statistical significance was not achieved, the trend of change observed was 
similar to what was observed with 2DE. The same was observed when peroxiredoxin II level 
from right ventricles of aerobic and I/R hearts was measured by immunoblot analysis  (Fig 
2.7D, p=0.07). 
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Figure 2.7 
Validation of 2DE results by immunoblotting.  The results obtained by 2DE were validated using 
immunoblotting.  (A) Protein levels of myosin light chain 2 and 2-enoyl-CoA hydratase in right and left 
ventricle samples from aerobic hearts; (B) Protein levels of peroxiredoxin II in right and left ventricle 
samples from I/R hearts; (C) Protein levels of myosin light chain 2 in left ventricle samples from 
aerobic and I/R hearts; (D) Protein levels of peroxiredoxin II in right ventricle samples from aerobic 
and I/R hearts.   n=3/group  * p<0.05  
 
 
42 
 
 
2.6 Discussion 
 
Proteomics provides a powerful experimental approach for observing the global 
changes in protein expression (level and profile) in cells, tissues or whole organs, in both 
physiological and pathological conditions (152-153). Using a proteomics approach, several 
studies have examined differences in protein expression developed in different subcellular 
compartments of hearts and alteration in the protein expression due to I/R induced injury in 
isolated hearts (54, 154-158). However, very little is known about differences between left 
and right ventricle proteomes. Up to date, only one study on proteomes of left and right 
ventricle in physiological conditions has been reported (144). 
In the majority of the studies using a proteomics approach, two-dimensional 
electrophoresis (2-DE) is a basic technique. 2-DE is the technique of choice due to its relative 
simplicity and low cost. 2-DE is able to resolve approximately 1,000 proteins, depending on 
the gel size (159). However, the number of measurable proteins visible in 2-DE depends on 
the dynamic range of protein concentration in the available sample and is estimated to be 
approximately 10,000 (160). Because measurement of levels of high and low abundant 
proteins in 2-DE has a high associated error (the level of protein spots are either saturated or 
close to the detection limit), we have analyzed only proteins with expression levels between 2 
and 500 arbitrary units.  
In our study of left and right ventricular proteomes from I/R heart, significant 
differences in protein expression profile were found. In aerobic conditions sarcomeric 
proteins, such as MLC2, α-actin and myosin heavy chain 5, are differently expressed between 
left and right ventricles, with MLC2 levels being higher in the left ventricle. MLC2 has been 
described to be an important contractile protein for the regulation of contractility and force of 
contraction (43) and the left ventricle responsible for the systemic circulation. Hence it is 
logical to assume that the higher level of MLC2 in the left ventricle is associated with a need 
to regulate contraction, in contrast to the right ventricle which has a lower contractile work 
demand. Also, in I/R left ventricle, the level of MLC2 was decreased while the level of a 
fragment of myosin heavy chain 5 was increased. The decrease of the level of the contractile 
proteins can be explained by the degradation of MLC-2 by MMP-2 (145), and the 
degradation of myosin heavy chain by MMP-9 (161). These findings are in line with the 
paradigm that I/R causes contractile dysfunction. The loss of a key contractile regulatory 
protein (MLC2), associated in increased degradation of myosin heavy chain 5 (important 
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structural and kinetic protein) provides insights as what the molecular mechanisms of left 
ventricular contractile dysfunction might be.  
Interestingly, no changes in the levels of sarcomeric proteins in right ventricle from 
I/R hearts in comparison to aerobic ventricle were observed. Again, this can be explained by 
fact that the contractile workload of the right ventricle is lower than the left ventricle. Under 
aerobic conditions, the left and right ventricle proteomes differ by expressing different levels 
of the mitochondrial antioxidant defensive protein peroxiredoxin 3, and the cytoskeleton 
protein vimentin. Peroxiredoxin 3 is less abundant in the left ventricle. Since peroxiredoxin 3 
is a mitochondrial antioxidant protein and the left ventricle has very high metabolic and 
respiratory rates, the decreased levels may result from the different metabolic and respiratory 
rates between the two ventricles. Interestingly, peroxiredoxin 2 was upregulated in right I/R 
ventricle, in comparison to aerobic right ventricle. Nonetheless the levels of peroxiredoxin 2 
in I/R conditions are still lower in the right than in the left ventricle. It appears as though left 
and right ventricle responses to oxidative stress by peroxiredoxin are isoform specific, with 
the left ventricle preferring peroxiredoxin 3 while the right ventricle relies on peroxiredoxin 2. 
Vimentin is more abundant in the left ventricle and it can be explained by the higher 
contractile work demand. In addition, vimentin is associated with lipid metabolism which 
correlates with higher lipid metabolism for energy production in the left ventricle (162-163).  
Two isoforms of α actin were significantly increased in the left ventricle in response 
to I/R. Actin is an important contractile protein. Although the general paradigm is that I/R 
causes degradation of cardiac contractile proteins, it is possible that the observed increase in 
actin protein levels is associated with an adaptive mechanism by the cardiomyocytes to 
decreased contractility and contractile efficiency. 
In our study we observed changes in the levels of heat shock proteins (HSP) 70 and β-
6. The level of HSP 70 decreased in left I/R ventricle but increased in the right I/R ventricle. 
HSP β-6 levels increased in both left and right I/R ventricles. We observed higher level of 
HSP 70 in left ventricle whereas HSP β-6 level was lower when the levels of these proteins 
from left and right ventricles of I/R hearts were compared. It has been reported that HSP 70 is 
upregulated during development of human heart failure (164). Our observations also have 
shown the upregulation (higher level) of HSP 70 in I/R injury, mainly in the left ventricle.  
During myocardial ischemia, myocyte stress leads to mitochondrial damage. An 
increase of the permeability of mitochondrial pores leads to swelling of the mitochondrial 
matrix and subsequent rupture of the outer membrane and development of irreversible injury 
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(165).  The mechanism of ischemic injury that induces mitochondrial protein level changes is 
complex. It may include the release of mitochondrial proteins (158, 166), changes in turnover 
of these proteins (balance between protein synthesis and protein degradation) (167-169) or 
post-translational modification that significantly change the pI or MW of the proteins (156). 
It is interesting to note the similarities and differences between right and left ventricles in 
response to ischemia. The level of HSP 8, HSP β -6, and subunits of ATP synthase were down 
after I/R stress in both right and left ventricles. However, while the left ventricle proteome 
responds to ischemia by an increase in the levels of structural proteins (such as α actin and 
cardiac myosin heavy chain 5), the right ventricle proteome adapts by modification of a 
group of mitochondrial proteins involved in energy metabolism. 
Van Eyk and co-workers subjected rabbit ventricular myocytes to conditions 
mimicking ischemia and the protein analysis revealed alteration in protein pattern especially 
in proteins involved in mitochondrial energetics, chaperoning and stress-response (156). 
Similarly, separate studies of mitochondrial proteomes have been performed in perfused 
rabbit hearts subjected to I/R (157). The authors identify 25 proteins involved in 
mitochondrial respiratory chain and energy metabolism differentially expressed in the I/R 
heart (157). Of the 25 proteins described by the authors to be changed by I/R, 3 were also 
identified by us to be changed by I/R or differentially expressed in right and left ventricles. 
These proteins were enoyl-CoA hydratase, ATPsynthase and α-actin. Also, the pattern of 
protein level changes in our study is identical to the one reported. 
Generally, our results are consistent with the reports describing the alteration of the 
protein expression in heart tissue in response to ischemic stress. Similar to the alteration in 
protein expression in human heart affected by ischemia (170), we have found that the altered 
proteins belong to three categories: (i) mitochondrial proteins involved in energy metabolism, 
(171) cytoskeletal (e.g. myosin light chain proteins), and (iii) stress response (e.g. HSP). 
To our knowledge, this is the first report concerning the comparison of the protein 
expression profile in left ventricle versus right ventricle of isolated heart, together with the 
study of the alteration of protein expression profile under ischemic stress.  
The significant difference in protein abundance between left and right ventricle and between 
aerobic and ischemic heart tissue has occurred in wide range of protein levels.  
Our findings are particularly important when interpreting results from cardiovascular 
studies that use either whole rat heart or isolated rat cardiomyocytes. While the use of whole 
heart homogenates for studying the molecular mechanism involved in cardiovascular 
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pathologies is a common procedure, our data raises the question of how accurate these 
observations are, in light of the proteomic difference of right and left ventricles.  
On the other hand the isolated adult cardiomyocytes are commonly used for the study 
of single cell contractility and calcium signaling. Due to the morphology of the cells, 
researchers have opted out to isolate right ventricle cardiomyocytes since it provides a more 
homogeneous population. Our data suggest that the observations made in isolated 
cardiomyocytes cannot be transposed to left ventricle or whole heart processes since the 
proteomes of left and right ventricles are distinct under aerobic conditions and respond very 
differently to I/R. 
Our data provide evidence that the right and left ventricles of the heart respond 
differently to I/R.  This is particularly important when dealing with clinical scenarios of 
global or regional ischemia. Although many studies have examined I/R injury and possible 
therapeutic strategies, the exact molecular and cellular mechanisms continue to be elusive 
and require more study.  
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3.1 Preface 
 
The manuscript presented here has been published in the journal Journal of Proteomics 
(Lin et al. 2012). This manuscript addressed objectives 1 and 3 of my PhD project. 
1. To identify proteomic profile in the heart subjected to I/R injury  
3. To determine the effect of the Myosin Light Chain Kinase Inhibitor ML-7 on the 
proteome of hearts subjected to I/R injury 
As we found in the previous study that energy metabolic proteins are regulated during 
I/R, and it has been shown the myosin light chain kinase (MLCK) is involved in the 
development of I/R injury. In this study, we show that myosin light chain kinase (MLCK) 
inhibitor ML-7 potentially protects the heart against I/R injury. Decreased level of energy 
metabolism proteins associated with ATP synthesis were identified in I/R group. This 
decrease suggests that ATP synthesis is inhibited during I/R, which might be related to 
protein kinase, such as MLCK. The changes in metabolic enzymes and structural proteins’ 
levels and their regulation by ML-7 suggest that the cardioprotective effect of ML-7 involves 
energy production and structural modulation.  
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3.2 Abstract 
 
In the development of ischemia/reperfusion (I/R) injury, the role of the myosin light 
chain (MLC) phosphorylation has been given increased consideration. ML-7, a MLC kinase 
inhibitor, has been shown to protect cardiac function from I/R, however the exact mechanism 
remains unclear.  
Isolated rat hearts were perfused under aerobic conditions (controls) or subjected to 
I/R in the presence or absence of ML-7. Continuous administration of ML-7 (5 μM) from 10 
min before onset of ischemia to the first 10 min of reperfusion resulted in significant recovery 
of heart contractility. Analysis of gels from two-dimensional electrophoresis revealed eight 
proteins with decreased levels in I/R hearts. Six proteins are involved in energy metabolism: 
ATP synthase beta subunit, cytochrome b-c1 complex subunit 1, 24-kDa mitochondrial 
NADH dehydrogenase, NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, 
cytochrome c oxidase subunit, and succinyl-CoA ligase subunit. The other two proteins with 
decreased levels in I/R hearts are: peroxiredoxin-2 and tubulin. Administration of ML-7 
increased level of succinyl-CoA ligase, key enzyme involved in the citric acid cycle.  
The increased level of succinyl-CoA ligase in I/R hearts perfused with ML-7 suggests 
that the cardioprotective effect of ML-7, at least partially, also may involve increase of 
energy production. 
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3.3 Introduction 
 
Myocardial infarction (MI), congestive heart failure and atherosclerosis are the main 
co-morbidities of ischemic heart disease, and are among the most common causes of death 
(172-173). Coronary reperfusion therapy is a well-established therapeutic strategy for the 
treatment of MI for over twenty years (174). However, newly returning blood flow to 
previously ischemic myocardium damages the cells within the myocardial tissues in what is 
called ischemia/reperfusion (I/R) injury, and up until now, the management of MI has mainly 
focused on the acute reperfusion of the previously ischemic myocardium (175). Present 
therapeutic strategies have few effective treatments focused on reducing the damage of I/R 
injury. Therefore, from a therapeutic point of view, it would be vital to target the active 
mediators of I/R injury and regulate these mediators in order to improve cell function and 
survival. In summary, the underlying mechanisms involved in the pathogenesis of myocardial 
I/R injury are complicated and involve the interactions of different pathways. 
Currently, the role of the myosin light chain kinase (MLCK) pathway in the 
development of cardiovascular disease and I/R injury has gained attention (50). MLCK also 
known as MYLK is a Ca2+/calmoduline activated serine/threonine-specific protein kinase that 
phosphorylates the 20kD regulatory light chain of myosin (51-52). Phosphorylation of 
cardiac myosin heavy chains and light chains by a kinase, such as MYLK3, potentiates the 
force and the rate of cross-bridge recruitment in cardiac myocytes (53). The MLCK is 
activated by the extracellular-regulated kinase (ERK) (55). The MLCK pathway has been 
reported to be involved in the pathology of several cardiovascular disorders (56-57), and it 
has been shown that the inhibition of MLCK protects heart from I/R injury by regulation of 
phosphorylation of MLC (55, 58). MLCK can be inhibited by ML-7, a membrane permeable 
agent (55). It has been reported that ML-7 protects the heart against I/R injury (50), and has 
beneficial effects in heart failure (55), brain injury (90) and glaucoma (91). 
The phosphorylation of MLC also is regulated by Rho kinase pathway. The active 
form of Rho, GTP-Rho activates Rho kinase (ROCK). ROCK phosphorylates the myosin 
binding subunit of myosin phosphatase inhibiting its activity, thus increasing phosphorylation 
of MLC2 of myosin II (61-63). It is well established that the inhibition of ROCK protects I/R 
hearts from contractile dysfunction (67). This research lab has recently indicated that the 
mechanism of protection of I/R hearts, in addition to inhibition of ROCK may up-regulate the 
protein  involved in an increase of energy production (67).  
51 
 
Considering the limited information about the effectors of the MLCK pathway and the 
wide spectrum of action for MLCK inhibitors action in I/R injury we hypothesized that the 
beneficial effects of ML-7 are well beyond regulation of contraction through phosphorylation 
or dephosphorylation of MLCs. The objective of this study is to identify possible additional 
molecular targets involved in the mechanism of cardioprotection by ML-7 with focus on 
energy production. 
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3.4 Materials and methods 
 
             The experimental procedures described below conform to the Guide to the Care and 
Use of Experimental Animals published by the Canadian Council on Animal Care. 
 
3.4.1 Heart perfusion and I/R protocol 
Male Sprague–Dawley rats (weighing 250–300 g) were anesthetized with 
pentobarbital (60 mg/kg). Hearts were excised and perfused through the aorta utilizing the 
Langendorff method at constant pressure (60 mmHg) with Krebs–Henseleit buffer at 37°C as 
previously described (127). Hemodynamic function was monitored during the entire protocol. 
Left ventricular developed pressure was calculated as the difference between systolic and 
diastolic pressures from the left ventricular pressure trace. The rate-pressure product (RPP) 
was calculated as the product of the spontaneous heart rate and left ventricular developed 
pressure. Control hearts (n=6) were aerobically perfused for 75 min. The ischemic hearts (I/R, 
n=6) were aerobically perfused for 25 min, followed by 20 min of global no-flow ischemia by 
closing of aortic inflow line (Emka Langendorff perfusion system, Paris, France) and 30 min 
of aerobic reperfusion. ML-7, when present, was infused for 10 min before the onset of 
ischemia and during the first 10 min of reperfusion at concentrations of 1, 3 and 5 μM 
(n=6/group). The hearts were subsequently frozen for biochemical studies. 
 
3.4.2 Myosin light chain kinase (MLCK) inhibitor 
            ML-7 (Sigma Aldrich, St Louis, MO, USA), 1-(5-iodonaphthalene-1-sulphonyl) 1H-
hexahydro 1, 4-diazepine hydrochloride, a selective inhibitor of myosin light chain kinase 
 
3.4.3 Preparation of heart extracts for two-dimensional electrophoresis (2-DE) 
Protein samples for 2-DE were prepared by mixing frozen (-80ºC), powdered heart 
tissue (40–60 mg wet weight) with 200 mL sample/rehydration buffer (8 mol/L urea, 4% 
CHAPS, 10 mmol/L DTT, 0.2% Bio-Lytes 3/10 (Bio-Rad, Hercules, CA, USA)) at room 
temperature. Samples were sonicated twice for 5 seconds and centrifuged for 10 min at 10 
000 g at 4ºC to remove any insoluble particles. Protein content of the heart extract in 
sample/rehydration buffer was measured with the Bio-Rad protein assay. For other 
biochemical studies, frozen heart tissue powder was homogenized on ice in 150 mM NaCl, 
50 mmol/L Tris-HCl (pH 7.4) containing protease inhibitor cocktail and 0.1% Triton X-100. 
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Homogenates were centrifuged at 10,000 g for 10 min, and the supernatant was collected and 
stored at -80ºC until further use. 
 
3.4.4 Two-dimensional electrophoresis 
Heart extract protein (400 mg) was applied to 11 cm immobilized pH gradient (5-8) 
strips (IPG, Bio-Rad) and equilibrated for 16 to 18 hours at 20ºC in rehydration buffer. For 
isoelectrofocusing, the Bio-Rad Protean isoelectrofocusing cell was used as previously 
described (22, 166). Next, 2-DE was carried out using Criterion precast gradient gels with 8–
16% acrylamide (Bio-Rad). To minimize variations in resolving proteins during the 2-DE run, 
12 gels were run simultaneously using a Criterion Dodeca Cell (Bio-Rad). The 
reproducibility of 2-DE and quality of protein loading has been previously verified by us (22, 
150, 176).  After separation, proteins were detected with Coomassie Brilliant Blue R-250 
(Bio-Rad). All the gels were stained in the same bath. Developed gels were scanned with the 
GS-800 Calibrated Densitometer (Bio-Rad). Quantitative analysis of spot intensity from 2-
DE was measured with PDQuest 8.01 software (Bio-Rad), and intensities of the separate 
bands from immunoblotting were analyzed and expressed in arbitrary units with Quantity 
One 4.4 measurement software (Bio-Rad). An arbitrary protein spot sensitivity threshold was 
used to detect changes of protein levels. This threshold determines significant changes in spot 
size, and intensity and is based on four parameters: largest and smallest spot area, minimum 
peak value sensitivity and noise filter level. The arbitrary threshold chosen by us eliminates 
from analysis low abundant protein spots that may result in an inaccurate identification by 
MS. Equal protein loading was additionally verified by measurement of tropomyosin level in 
2-D gels.  
 
3.4.5 Mass spectrometry (MS) 
Protein spots whose levels were changed by I/R and further affected by ML-7 
(decreased, normalized or increased) were manually excised from the 2-DE gel and processed 
using a MassPrep Station from Micromass (Waters, Milford, MA, USA) according to the 
methods supplied by the manufacturer. Briefly, the excised gel fragment containing the 
protein spot was first destained in 200 mL of 50% ACN with 50 mM ammonium bicarbonate 
at 37ºC for 30 min. Next, the gel was washed twice with water. The protein extraction was 
performed overnight at room temperature with 50 mL of a mixture of formic acid: water: 
isopropanol (1:3:2, v:v:v). The resulting solution was then subjected to trypsin digestion and 
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MS analysis. For electrospray, quadruple time-of-flight analysis, 1 mL of the solution was 
used. LC/MS/MS was performed on a CapLC highperformance liquid chromatography unit 
(151) coupled with a quadruple time-of-flight-2 mass spectrometer (Micromass from Waters). 
A mass deviation of 0.2 was tolerated and one missed cleavage site was allowed. Resulting 
values from MS/MS analysis were used to search against the NCBInr and Swiss-Prot 
databases for Rattus norvegicus. We used the MASCOT (www.matrixscience.com) search 
engine to search the protein database and identify the protein. Mowse scoring algorithm was 
used to justify accuracy of protein identification, which is incorporated in the MASCOT 
search engine. 
 
3.4.6 Western blot analysis 
Protein (30 mg) from heart homogenate was separated using 12% SDS-PAGE and 
transferred to a PVDF membrane (Bio-Rad). Protein level of SUCLA2 (succinate-CoA ligase, 
ADPforming, β subunit) was measured using mouse monoclonal anti-SUCLA2 antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), NDUFV2 (NADH dehydrogenase 
[ubiquinone] flavoprotein 2) was measured using rabbit polyclonal anti-NDUFV2 antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), peroxiredoxin-2 was measured using 
rabbit polyclonal anti- peroxiredoxin-2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA). Band densities were measured using Versa Doc 5000 and Quantity One 4.6 software 
(Bio-Rad). Equal protein loading was additionally verified by measurement of tropomyosin 
level with mouse monoclonal anti-tropomyosin antibody (abcam, Cambridge, MA, USA) 
 
3.4.7 PKC activity assay 
Protein kinase C (PKC) activity was determined using a commercially available PKC 
assay kit from Promega (Madison, WI, USA) according to the supplier’s instructions. Briefly, 
crude heart homogenates from frozen heart samples were homogenized in PKC extraction 
buffer using a sonicator. PKC was semi-purified using a 1 ml DEAE cellulose column. The 
PKC enriched fraction (9 µg protein/reaction) was incubated with PepTag C1 peptide and 
incubated for 90 min at 30°C. The reaction was stopped by placing tubes in a boiling water 
bath. After cooling, the phosphorylated and non-phosphorylated peptides were separated in a 
0.8% agarose gel at 100 V for 30 min. Detection of PepTag C1 peptide was performed 
using the VersaDoc 5000 and Quantity One software (BioRad, Hercules, CA, USA). The 
decrease in non-phosphorylated PepTag C1 peptide was used as an indicator of increased 
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PKC activity. 
 
3.4.8 Statistical analysis 
The protein spot levels were analyzed using t-test and Mann–Whitney U-test, which is 
incorporated in the PDQuest measurement. The proteins of interest were identified by MS. 
ANOVA and Kruskal–Wallis test were used in functional studies. Data are expressed as the 
mean ± SEM. 
 
 
 
 
 
 
            . 
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3.5 Results 
 
3.5.1 Protection of cardiac mechanical function by ML-7 
Hearts subjected to 20 min global no-flow ischemia and 30 min reperfusion showed a 
significant decrease of mechanical function.  The rate-pressure product (RPP) was decreased 
by approximately 60% (Figure 3.1A) and coronary flow decreased by 65% (Figure 3.1B).  
Administration ML-7 (MLCK inhibitor) significantly improved the RPP and coronary flow 
of isolated heart (Figure 3.1).  The pharmacological effect of ML-7 was dose-dependent, and 
treatment with 5 μM ML-7, the highest dose used in our experimental conditions, elevated 
the recovery of RPP up to 75% and 100% of coronary flow in comparison to aerobic hearts 
(Figure 3.1). 
 
Figure 3.1 
Hemodynamic parameters of retrograde rat heart perfusioned with or without MLC kinase inhibitor 
ML-7.  (A) Mechanical function presented as rate-pressure product (RPP) and (B) coronary flow at the 
end of perfusion protocol.*p<0.05 versus aerobic, $p<0.05 versus I/R. 
 
3.5.2 Identification of protein spots from aerobic versus I/R protocol group 
Protein extracts from hearts perfused aerobically (control) with or without I/R 
protocol were separated by 2-dimensional electrophoresis (2-DE) (Fig. 3.2). Analysis of the 
protein spot intensity variation (using an arbitrary threshold) detected nine protein spots with 
significantly decreased level in the I/R hearts, in comparison to the control group (Fig. 3.3).  
All nine protein spots were identified by mass spectrometry (MS) (Table 3.1). Six protein 
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spots were identified as mitochondrial enzymes involved in energy production and included: 
ATP synthase beta unit, cytochrome b-c1 complex subunit 1, 24-kDa NADH dehydrogenase 
precursor, NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, cytochrome c oxidase 
subunit 5A, precursor, and succinyl-CoA ligase[ADP-forming] subunit beta, mitochondrial. 
Two protein spots were identified as peroxiredoxin-2 and selenium-binding protein. The 
ninth decreased protein spot was tubulin, a structural protein (Fig.3.3). 
          Usually the measurement of level of actin, glyceraldehyde-3-phosphate 
dehydrogenese (GAPDH) or tubulin is used as an indicator of equal protein loading in 
electrophoretic techniques.   Previously, we showed that I/R injury in isolated hearts altered 
the level of glyceraldehyde-3-phosphate dehydrogenese (GAPDH). The level of actin is 
significantly decreased in the heart with myocardial infarction when measured by 
immunobloting (177). In this study we observed changes in tubulin level. The level of 
tropomyosin was not affected in 2-DE and immunobloting analysis.  From this we used the 
measurement of tropomyosin levels as a control of protein loading (Fig. 3.3B, 3.5B, 3.6C 
and 3.7B).   
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Table 3.1Identification of protein spots from aerobic VS I/R protocol group 
a) Ions score is -10*Log (P), where P is the probability that the observed match is a random 
event. Individual ions scores > 37 indicate identity or extensive homology (p<0.05). 
b) The arrows (↑↓) indicate statistically significant changes in protein levels (versus aerobic 
protocol. 
 
 
 
 
 
Protein spot NO. Mowse 
score a) 
Queries 
matched 
Sequence 
coverage (%) 
pI/MW 
(kDa) 
Identified protein 
Energy 
production 
          
187 ↓b) 490 15 15% 4.92/51.171 ATP synthase beta 
subunit 
195 ↓ 106 2 2% 5.57/ 53.500 cytochrome b-c1 
complex subunit 1, 
mitochondrial 
precursor 
196 ↓ 668 24 34% 6.00/ 26.854 
24-kDa 
mitochondrial 
NADH 
dehydrogenase 
precursor 
197 ↓ 635 13 13% 5.87/ 24.411 NADH 
dehydrogenase 
[ubiquinone] iron-
sulfur protein 8, 
mitochondrial 
198 ↓ 317 11 13% 6.08/ 16.347 
cytochrome c 
oxidase subunit 5A, 
mitochondrial 
precursor 
204 ↓ 309 
 
13 
 
16% 7.57/ 50.616  succinyl-CoA ligase 
[ADP-forming] 
subunit beta, 
mitochondrial 
Structural 
proteins 
     
185 ↓ 82 2 2% 4.79/ 50.225 tubulin beta-2C 
chain 
Others      
194 ↓ 151 8 14% 5.34/ 21.941 peroxiredoxin-2 
203 ↑ 314 15 22% 6.10/53.069 selenium-binding 
protein 1 
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Figure 3.2 
Two-dimensional electrophoresis (2-DE) of heart homogenates.  Representative gels of 2-DE of 
protein extracts from aerobically (control) perfused hearts and I/R hearts.  The arrows indicate the 
protein spots significantly changed by I/R.   
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Figure 3.3 
Densitometric analysis of protein spots from 2-DE gels from aerobically (control) perfused hearts and 
I/R hearts.  (A) Results of densitometric analysis of protein spots affected by I/R.  (B) Level of 
tropomyosin in aerobic and I/R hearts (control of equal protein loading).  *p<0.05 versus aerobic, 
$p<0.05 versus I/R. 
 
 
3.5.3 Effects of ML-7 treatment on the proteome of hearts subjected to I/R 
Heart protein extracts from aerobic control, I/R and I/R treated with 5 μM of ML-7 
were analyzed by 2-DE (Fig 3.4). Using an arbitrary threshold for variation, we detected 
three protein spots affected by ML-7 treatment and we identified them (Table 3.2). These 
spots were identified as structural proteins tubulin beta-2 C chain, vimentin and an energy 
production modulator mitochondrial succinyl-CoA ligase [ADP-forming] subunit beta. All of 
them revealed a similar profile of change being significantly increased in I/R hearts treated 
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with ML-7 (Fig. 3.5). The protein level of vimentin was increased only in hearts treated with 
ML-7. The tubulin level was normalized by ML-7. In contrast, the protein level of succinyl-
CoA ligase in ML-7 treated I/R hearts was significantly increased in comparison to control 
and I/R hearts (Fig. 3.5). 
 
 
Table 3.2 Identification of protein spots from I/R protocol VS I/R plus ML-7 protocol group 
a) Ions score is -10*Log (P), where P is the probability that the observed match is a random 
event.  Individual ions scores > 37 indicate identity or extensive homology (p<0.05). 
b) The arrows (↑↓) indicate statistically significant changes in protein levels (versus I/R 
protocol) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein spot NO. 
 
Mowse 
score a) 
Queries 
matched 
Sequence 
coverage (%) 
pI/MW 
(kDa) 
Identified protein 
Energy 
production 
          
204 ↑b) 309 13 16% 7.57/ 50.616  succinyl-CoA 
ligase [ADP-
forming] subunit 
beta, mitochondrial 
Structural 
proteins 
     
183 ↑ 144 6 10% 5.06/ 53.757 vimentin 
185  82 2 2% 4.79/ 50.225 tubulin beta-2C 
chain 
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Figure 3.4 
Effect of ML-7 treatment on the cardiac proteome.  Representative 2-DE gels from I/R and I/R+ML-7 
hearts.  Arrows indicate the protein spots were significantly changed by ML-7 treatment.   
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Figure 3.5 
Densitometric analysis of protein spots from 2-DE gels from aerobically (control) perfused hearts and 
I/R hearts with and without ML-7.  (A) Results of analysis of ML-7 on protein spot levels.  (B) Level of 
tropomyosin in analyzed hearts (control of equal protein loading).  *p<0.05 versus aerobic, $p<0.05 
versus I/R. 
 
3.5.4 Western blot analysis of identified protein 
To verify results from 2-DE we performed immunoblotting for some of proteins. 
Immunoblot analysis of peroxiredoxin-2 and NADH dehydrogenase [ubiquinone] 
flavoprotein 2 (NDUFV2) showed decreased level of these proteins in I/R hearts what is 
similar to the results from obtained from 2-DE (Fig. 3.6). Analysis of changes of SUCLA2 
levels in all 3 groups of hearts also showed similar results to these obtained from 2-DE (Fig. 
3.7). 
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Figure 3.6 
Verification of results from 2-DE by analysis of changes of protein level with immunoblotting: 
(A)Peroxiredoxin-2; (B) NADH dehydrogenase [ubiquinone] flavoprotein 2; (C) Tropomyosin, (control 
of equal protein loading).  n=3/group; *p<0.05 versus aerobic. 
 
 
 
Figure 3.7 
Analysis of Succinate-CoA ligase level s by immunoblotting (A) and (B) Tropomyosin, (control of equal 
protein loading) in control, I/R and I/R + ML-7 hearts.  *p<0.05 versus aerobic, $p<0.05 versus I/R. 
 
3.5.5 Protein kinase C (PKC) activity analysis 
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It has been reported that activation of PKC epsilon is central to cardioprotection 
against ischemic stress (178) and that ML-7 inhibits PKC activity (179). In our study we 
observed a significant increase of PKC activity in response to I/R injury, however 5 μM ML-
7 did not affect PKC activity in hearts subjected to I/R (Fig. 3.8).  
 
Figure 3.8 
Protein kinase C activity in control hearts or subjected to I/R in the presence or absence of ML-7.  
(n=4).  *p<0.05 versus aerobic 
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3.6 Discussion  
 
Despite a large number of studies on heart injury by ischemia/reperfusion (I/R), the 
molecular basis of cardiac dysfunction caused by I/R is still unclear. Utilizing a proteomics 
approach, some studies have demonstrated differences in protein expression in different 
subcellular compartments of hearts and changes in the protein expression due to I/R injury in 
isolated hearts (155, 176). Recently, studies have shown that myocardial I/R injury, with the 
contribution of reactive oxygen species (15), activate some protein kinases (48, 98, 180-181). 
The central importance of MLC phosphorylation in contractile state of cardiomyocyte has 
been demonstrated previously. Phosphorylation of MLC at Ser19/Thr18 by activated MLC 
kinase (MLCK) or inhibition of MLC phosphatase (MLCP) plays a critical role in the 
development and regulation of contractile forces within cells (182). The cardioprotective 
effects of inhibition of the MLCK pathway by ML-7 have been described in different animal 
models but have been mainly associated with protection of contractile function via the 
regulation of the phosphorylation status of myosin. It was shown that ML-7 is specific, albeit 
a relatively weak inhibitor of smooth muscle MLCK. Mitogen and stress activated protein 
kinase 1 (MSK 1) was also inhibited by ML-7, although much less potent (179). The 
specificity of ML-7 inhibitory action depends on the origin MLCK. There is a cMLCK 
expressed only in cardiac muscle similar to the tissue-specific expression of skeletal and 
smooth muscle MLCK. The cardiac regulatory chain of myosin is not a good substrate for 
smooth muscle MLCK which probably phosphorylates non-muscle cytoplasmic myosin IIB 
(58).   
Previously, we found that I/R treatment of isolated hearts resulted in reduction of 
protein levels. The most affected were the structural proteins, such as MLC1 and 
mitochondrial proteins involved in energy metabolism such as ATP synthase subunits, were 
shown to be affected by I/R (166). In this study, we found that I/R injury resulted in a similar 
pattern of protein alteration in comparison with aerobic control group. In the I/R affected 
group, six of the energy metabolism proteins were identified as significantly different from 
aerobic control: ATP synthase beta subunit (electron transport chain complex V), cytochrome 
b-c1 complex subunit (electron transport chain complex III), 24-kDa mitochondrial NADH 
dehydrogenase (electron transport chain complex I), cytochrome c oxidase subunit (electron 
transport chain complex IV),NADH dehydrogenase [ubiquinone] iron-sulfur protein 8 
(electron transport chain complex I) and succinyl-CoA ligase [ADP-forming] subunit beta, 
mitochondrial. Five of these proteins are involved in the most important process in ATP 
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production, the electron transport chain. Some reports have shown that global ischemia 
down-regulates genes and proteins related to mitochondrial function, energy production, co-
factor catabolism, and the generation of precursor metabolites of energy (183). During 
myocardial ischemia, the electron flow along the respiratory complexes in mitochondria is 
inhibited, and the mitochondrial oxygen consumption as well as ATP production is decreased 
(183). Increased ROS formation during I/R injury leads to ischemic mitochondrial damage 
and is causally involved in cell death. Release of ROS or pro-apoptotic factors from damaged 
mitochondria enhances cardiomyocyte injury. Taken together, I/R injured mitochondria (e.g. 
due to limited oxidative phosphorylation), mitochondria themselves may contribute to 
myocardial injury.  
The level of peroxiredoxin-2 decreased during I/R, in comparison with aerobic control 
group. Peroxiredoxins are a ubiquitous family of antioxidant enzymes which also control 
cytokine-induced peroxide levels and mediate signal transduction in mammalian cells. 
Similar trend was observed in the tissue of human failing hearts where the level of 
peroxiredoxin-2 was down-regulated (~1.5 fold) in contrast to peroxiredoxin-6 which was 2-
fold up-regulated (184). 
We also indentified the up-regulation of selenium-binding protein. Selenium is an essential 
trace mineral element involved in protection against oxidative damage through selenium-
dependent glutathione peroxidases and other selenoproteins, such as selenium-binding protein 
(185).  
Previously, we have shown that the inhibition of ROCK pathway of MLC1 
phosphorylation partially protected the mechanical function of heart during I/R (67). Recently, 
the inhibition of MLCK pathway of MLC1 phosphorylation revealed a similar level of 
protection on the mechanical function of the I/R heart, but the pattern of proteins altered by 
I/R plus ML-7 treatment was different. Inhibition of ROCK pathway in the isolated heart 
resulted in up-regulation of two glycolytic enzymes, LDH-B and GAPDH whereas ATP 
synthase subunits and mitochondrial CK levels were normalized (67). Inhibition of the 
MLCK pathway revealed the up-regulation of some structural and involved in energy 
production proteins. The reason for the differences in inhibitory action on ROCK and MLCK 
pathways may had occurred because it has been demonstrated the central importance of 
MLCK in regulating the contractile state not only in cardiomyocytes but also plays a role in 
endothelial cell barrier functions (186). 
We implicate the MLCK pathway in the regulation of the level of the proteins 
involved mainly in energy production and structural regulation. Inhibition of this pathway can 
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contribute to changes of energy production and structural regulation during I/R. In 
comparison with I/R group, ML-7 treated hearts subjected to I/R resulted in increased levels 
of several energy metabolism proteins and structural proteins. Two of those proteins were 
significantly increased, which are mitochondrial succinyl-CoA ligase [ADP-forming] subunit 
beta and vimentin. Succinyl-CoA ligase also is known as succinyl-CoA synthetase, which is 
an enzyme that catalyzes the reversible reaction of succinyl-CoA from succinate. This 
enzyme facilitates the coupling of the reaction to the formation of GTP or ATP. It plays a key 
role as one of the important catalysts involved in the citric acid cycle, located within the 
mitochondrial matrix of a cell. Vimentin plays a key role in anchoring and supporting the 
position of the organelles in the cytosol. Vimentin is attached to the nucleus, mitochondria, 
and endoplasmic reticulum (ER) either laterally or terminally (187). Vimentin Clips offer 
three different clips that show vimentin movement inside the cell. Vimentin is more abundant 
during I/R and it can be explained by the higher contractile work demand. In addition, 
vimentin is associated with lipid metabolism which correlates with higher lipid metabolism 
for energy production in I/R. Therefore, we conclude that the cardioprotective effect of 
inhibition of the MLCK pathway involves optimization of energy metabolism in I/R likely 
resulting in increased energy production, hence the observed increase in cardiac recovery 
after I/R. Despite the cardioprotective effect of ML-7 on the contractile protein MLC1 the 
additional pharmacological effect of ML-7 should be consider because not only ROS but 
asymmetric dimethylarginine (ADMA) significantly contributed to I/R heart injury. ADMA is 
the endogenous NOS inhibitor and can induce the MLCK synthesis in ischemic heart (188). 
The use of ML-7 can reduce the ADMA-induced heart injury. 
Another important observation from this study is fact that tropomyosin level is stable 
and is not affected by I/R and drug treatment. This feature allows use tropomyosin as a 
control of protein loading. The level of commonly used housekeeping proteins, such as  
glyceraldehyde-3-phosphate dehydrogenese (GAPDH) and actin, are affected in the model of 
I/R (67) or MI (177). Tubulin another protein used as a housekeeping protein was decreased 
in this studies and its level were normalized by ML-7. 
In summary, this study provides new insights into the molecular mechanisms of a 
broad variety of heart pathologies related to I/R injury. Also, we have shown the functional 
importance of MLCK during I/R, and as a result, the potential kinase inhibitors hold promise 
as novel strategies reducing the impact of cardiovascular disease. In addition, we propose 
ML-7 as a potential drug for new therapeutic strategies for treatment of MI. 
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4.1 Preface 
 
     This manuscript presented here has been published in the journal Journal of proteomics 
(Lin et al. 2014). This mauscript addressed the objective 4 in my PhD project. 
4. To analyze the inhibition of MMP-2 gene expression with small interfering RNA in 
isolated cardiomyocytes by proteomic analysis, with the focus on the degradation of energy 
metabolic proteins by MMP-2 
We have also shown that the inhibition of MMP-2 protects the heart from I/R injury. So 
far, we have only studied that MMP-2 degrades contractile proteins, but no one knows 
whether MMP-2 degrades energy metabolic proteins, or in the other words, inhibition of 
MMP-2 affects the energy metabolic proteins. This is why we started to study the proteomics 
of inhibition of MMP-2 in cardiomyocyte under aerobic condition. And we found that MMP-
2 is involved in the regulation of the energy metabolic proteins such as ATP sythase in normal 
physiological condition. 
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4.2  Abstract 
 
In this study we examined the effect of inhibition of MMP-2 expression, using siRNA, 
on the cardiomyocyte proteome.  
Isolated cardiomyocytes were transfected with MMP-2 siRNA and incubated for 24 
hours. Control cardiomyocytes from the same heart were transfected with scrambled siRNA 
following the same protocol. Comparison of control cardiomyocyte proteomes with 
proteomes from MMP-2 suppressed cardiomyocytes revealed 13 protein spots of interest (9 
protein spots increased; 4 decreased). Seven protein spots were identified as mitochondrial 
enzymes involved in energy production and represent: ATP synthase β subunit, 
dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase 
complex, cytochrome c oxidase subunit 5A, electron transfer flavoprotein subunit beta, 
NADH dehydrogenase (ubiquinone) 1 α subcomplex subunit 5 and a fragment of 
mitochondrial precursor of long-chain specific acyl-CoA dehydrogenase. Furthermore, 
precursor of heat shock protein 60 and Cu-Zn superoxide dismutase were identified.  Two 
protein spots corresponding to MLC1 were also detected. In addition, ATP synthase activity 
was measured and was increased by approximately 30%. 
           Together, these results indicate that MMP-2 inhibition represents a novel 
cardioprotective therapy by promoting alterations in the levels of mitochondrial enzymes for 
improved energy metabolism and by preventing degradation of contractile proteins needed for 
normal excitation-contraction coupling 
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4.3 Introduction 
 
Cardiac ischemia followed by reperfusion often results in the development of cardiac 
contractile dysfunction that limits the recovery and prognosis of patients. A number of 
pharmacological therapies are developed against ischemia/reperfusion (I/R) injury, however, 
the underlying molecular mechanisms of I/R injury and myocardial infarction (MI) remain 
unclear. 
 Matrix metalloproteinases (MMPs)  have been shown to play important roles in 
protein degradation in heart diseases including I/R injury [reviewed in (189)], but the targets 
and mechanisms are still unclear. Currently there are 20 known MMPs, but identifying which 
isoform contributes to the mechanisms underlying I/R injury requires further investigation. 
However, studies on the role of MMPs in cardiovascular diseases suggest that MMP-2 is a 
significant contributor and plays a major role in I/R heart injury [reviewed in (190)]. It has 
been shown that α-actinin, a structural protein (116), and contractile proteins, such as 
troponin I (114) , myosin light chain 1(MLC1) (22), titin (115), and MLC2 (145), are 
degraded by MMP-2 and this causes contractile dysfunction of I/R hearts.  Furthermore, it 
has been shown that inhibition of MMP-2 action protects these proteins and I/R hearts from 
contractile dysfunction  [reviewed in (191)].  
Despite extensive research on the role of MMP-2 in heart disease, the understanding 
of the biology of MMP-2 is far from satisfactory due to the lack of selective inhibitors. The 
MMP-2 inhibitors currently available are either broad inhibitors of all metalloproteinases or 
selective to one family of metalloproteinases (192).  The synthetic compounds currently used 
to inhibit MMP-2 include o-phenathroline, doxycycline or derivatives of hydroxamic acid 
such as Batimastat, Marimastat or Ilomastat. These compounds often affect the action of 
other proteolytic enzymes in addition to inhibiting MMPs.    
Endogenous protein inhibitors of MMP (TIMPs) are more suitable, however they still 
demonstrate a broad spectrum of MMP inhibition. Consequently, for the purpose of studying 
the biology of MMP-2 it is important to develop new strategies for selective/specific MMP 
inhibition. With the use of isolated cardiomyocytes, inhibition or reduction of MMP-2 
expression appears to be a very promising strategy to study the role of MMP-2 in heart.  
          Small interfering RNA (siRNA) has been shown in vitro to specifically reduce or 
totally inhibit MMP-2 synthesis (193). To selectively inhibit MMP-2 action and identify 
additional molecular targets of MMP-2, this study used MMP-2 siRNA to inhibit MMP-2 
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expression in isolated myocytes. Proteomic analysis was performed on isolated 
cardiomyocytes treated with or without MMP-2 siRNA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
75 
 
4.4 Experimental procedures 
 
         The experimental procedures described below conform to the Guide to the Care and 
Use of Experimental Animals published by the Canadian Council on Animal Care. 
 
4.4.1 Isolation of cardiomyocytes 
            Male Sprague-Dawley rats (weighing 100–150 g) were anaesthetized with sodium 
pentobarbital (60 mg/kg i.p.) and hearts were removed. Right ventricular myocytes were 
obtained by enzymatic digestion as previously described (194-195). After isolation, the cells 
were suspended in DMEM medium supplemented with 10% fetal bovine serum and 
antibiotics (100U/ml penicillin and 100μg/ml streptomycin). The quality of myocyte 
preparations was assessed by measurement of cell viability and cell contractility. The viability 
of cardiomyocytes was assessed by the trypan blue exclusion test. 
 
4.4.2 Primary culture of cardiomyocytes and siRNA transfection 
            Preparations of cardiomyocytes were incubated in 35 x 10mm cell culture plates 
(Nunc, Roskilde, Denmark) at concentrations of 2×105 cells per plate in DMEM medium 
(Lonza, Walkersville, MD, USA) supplemented with 10% (v/v) fetal bovine serum and 
antibiotics (100U/ml penicillin and 100μg/ml streptomycin) in a 95% air and 5% CO2 
incubator at 37°C. 
A mixture containing a pool of 3 target-specific 19-25 nucleotide small interfering 
RNAs (MMP-2 siRNA)  designed to knock down rat MMP-2 gene expression (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) was resuspended in RNAse-free water to make a 10 
μM solution in 10 mM Tris-HCl, pH 8.0, 20 mM NaCl, and 1 mM EDTA buffered solution. 
This solution was stored at -20°C. As a control, a scramble of siRNA (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) was used in the same conditions.   
After a 7 h stabilization period, cardiomyocytes were washed with siRNA transfection 
medium (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Next 0.8 μM of MMP-2 siRNA 
or scrambled siRNA in 200μl of transfection medium was incubated for 24 h at 37°C 
according to the manufacturer’s protocol. siRNA was removed  and cells were further 
incubated for 17 h in DMEM medium. The control cardiomyocytes from the same heart were 
incubated for a total 48 h in DMEM medium. The experimental protocol and analyzed cell 
groups are shown in Figure 1. 
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For assessment of transfection efficiency, plasmid containing cDNA with green 
fluorescent protein (GFP) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was transfected 
in the same way as the siRNA. 
 
 
Figure 4.1  
Experimental protocol outlining MMP-2 siRNA transfection.  Isolated cardiomyocytes were divided into 
3 groups.  Control group (incubated for 48 hours without any intervention) scramble siRNA group, 
(control to the MMP-2 siRNA group), and MMP-2 siRNA transfected group.  Total incubation time for 
all groups was 48 hours. 
 
 
4.4.3 Measurement of contractility of cardiomyocytes 
            Cardiomyocyte contractility was evaluated at the end of transfection. Control 
myocytes were incubated for the same period of time as cells transfected with siRNA. The 
contractility was measured from 100 μl of the cell suspension using IonOptix system and 
IonWizard 6.0 software (IonOptix, Milton, MA USA). After a stabilization period the 
chamber containing the cells was perfused with an oxygenated buffer at a constant 
temperature of 37°C. Cells were continuously paced with 1 Hz and 5 V (IonOptix MyoPacer, 
Milton, MA, USA). The contractility of cardiomyocytes is shown as a percent of peak 
shortening in comparison to the total non-contracted length. On average, 8-10 cells per 
sample were analyzed for 10 min to determine contractile function. 
 
4.4.4 Preparation of cell extracts 
            After the transfection procedure (48 h), cardiomyocytes were harvested and stored at -
80°C. For biochemical studies frozen cardiomyocytes were sonicated on ice for 5 seconds 
(twice) in 50 mM Tris-HCl (pH7.4) containing 3.1 mM sucrose, 1 mM DTT, 10 µg/mL 
leupeptin, 10 µg/mL soybean trypsin inhibitor, 2 µg/mL aprotinin, and 0.1% Triton X-100. 
Homogenates were then centrifuged at 10 000g at 4°C for 10 minutes. The supernatant was 
collected and stored at -80°C until further use.  
 
4.4.5 Measurement of MMP-2 activity 
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            Gelatin zymography was performed as described (122, 127) . Briefly, homogenates 
from cardiomyocyte preparations containing 30 μg of protein were applied to 8% 
polyacrylamide gel copolymerized with 2 mg/mL gelatin. After electrophoresis, gels were 
rinsed three times for 20 minutes in 2.5% Triton X-100 to remove SDS. The gels were then 
washed twice in incubation buffer (50 mM Tris-HCl, 5 mM CaCl2, 150 mM NaCl and 0.05% 
NaN3) for 20 minutes at room temperature and then placed in incubation buffer at 37°C for 
24 hours. The gels were stained using 0.05% Coomassie Brilliant Blue G-250 in a mixture of 
methanol:acetic acid:water (2.5:1:6.5, v:v:v) and destained in aqueous solution of 4% 
methanol and 8% acetic acid (v:v). Developed gels were scanned with GS-800 calibrated 
densitometer (Bio-Rad, Hercules, CA, USA) and MMP-2 activity was measured using 
Quantity One 4.6 software (Bio-Rad, Hercules, CA, USA). 
 
4.4.6 Immunoblot analysis 
            Protein (30 µg) from cardiomyocyte homogenate was separated using a 12% SDS-
PAGE gel and transferred to a PVDF membrane (Bio-Rad, Hercules, CA, USA). Myosin 
light chain 1 (MLC 1) was measured using mouse monoclonal anti-MLC1 antibody (Abcam, 
Cambridge, MA, USA) while MMP-2 was measured using rabbit monoclonal anti-MMP-2 
antibody (Abcam, Cambridge, MA, USA). Band densities were calculated using Versa Doc 
5000 and Quantity One 4.6 software (Bio-Rad, Hercules, CA, USA). Equal protein loading 
was additionally verified by measurement of tubulin level with mouse monoclonal antibody 
(Abcam, Cambridge, MA, USA). 
 
4.4.7 Immunocytochemistry 
            For immunocytochemistry, cardiomyocytes were seeded on polylysine-coated 
coverslips and followed the same siRNA transfection protocol. After permeabilization with 
0.25% Triton X-100 and fixation, cells were blocked for 1 h with PBS containing 5% bovine 
serum albumin (Sigma, St. Louis, MO, USA). Proteins of cardiomyocytes were labeled by 
overnight incubation (at 4°C) with rabbit anti-MMP-2 (Abcam, Cambridge, MA, USA)  
antibody diluted at 1:200 in blocking buffer followed by brief wash (three times; 10 min each) 
and incubation with Alexa Fluor 555-conjugated goat anti-rabbit secondary antibodies 
(Invitrogen, Carlsbad, CA, USA) at 1:1000 for 1 h. After Hoechst (Sigma, St. 
Louis, MO, USA) staining, the cover slips were mounted on newly cleaned slides using 
Prolong Gold Antifade Reagent (Invitrogen, Carlsbad, CA, USA ) and observed with a 
LSM700 laser scanning confocal microscope (Carl Zeiss, Oberkochen, Germany ) and 
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analyzed with the Zeiss Zen 2009 software, version 5.5 SPI (Carl Zeiss, Oberkochen, 
Germany ).  
 
4.4.8 Two-dimensional electrophoresis (2-DE) 
            Protein samples for 2-DE were prepared by mixing frozen (-80ºC) cardiomyocytes 
(40–60 mg wet weight) with 0.2 mL sample/rehydration buffer (8 mol/L urea, 4% CHAPS, 
10 mmol/L DTT, 0.2% Bio-Lytes 3/10 (Bio-Rad, Hercules, CA, USA) at room temperature. 
Samples were sonicated twice for 5 seconds and centrifuged for 10 min at 10 000 g at room 
temperature to remove any insoluble particles. Protein content of the cardiomyocytes 
homogenates in sample/rehydration buffer was measured with the Bio-Rad protein assay after 
suitable dilution of the homogenate.  
For other biochemical studies, frozen cells were homogenized on ice in 150 mM NaCl, 
50 mM Tris-HCl (pH 7.4) containing protease inhibitor cocktail and 0.1% Triton X-100. 
Homogenates were centrifuged at 10,000 g for 10 min, and the supernatant was collected and 
stored at -80ºC until further use. Protein content of the cardiomyocyte extract in homogenized 
buffer was also measured with the Bradford protein assay (Bio-Rad, Hercules, CA, USA). 
 Cardiomyocyte extract protein (400 µg) was applied to 11 cm immobilized pH 
gradient (3-10) strips (Bio-Rad, Hercules, CA, USA) and equilibrated for 16 to 18 hours at 
20ºC in rehydration buffer. For isoelectrofocusing, the Bio-Rad Protean isoelectrofocusing 
cell was used as previously described (22, 166). Next, 2-DE was carried out using Criterion 
precast gradient gels with 8–16% acrylamide (Bio-Rad, Hercules, CA, USA). To minimize 
variations in resolving proteins during the 2-DE run, 12 gels were run simultaneously using a 
Criterion Dodeca Cell (Bio-Rad, Hercules, CA, USA). The reproducibility of 2-DE and 
quality of protein loading has been previously verified by us (22, 150, 176).  After separation, 
proteins were detected with Coomassie Brilliant Blue R-250 (Bio-Rad, Hercules, CA, USA). 
All the gels were stained in the same bath. Developed gels were scanned with the GS-800 
calibrated densitometer (Bio-Rad, Hercules, CA, USA). Quantitative analysis of spot 
intensity from 2-DE was measured with PDQuest 8.01 software (Bio-Rad, Hercules, CA, 
USA), and intensities of the separate bands from immunoblotting were analyzed and 
expressed in arbitrary units with Quantity One 4.4 measurement software (Bio-Rad, Hercules, 
CA, USA). An arbitrary protein spot sensitivity threshold was used to detect changes in 
protein levels. This threshold determines significant changes in spot size and intensity, and is 
based on four parameters: largest and smallest spot area, minimum peak value sensitivity and 
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noise filter level. The arbitrary threshold chosen by us eliminates from analysis low abundant 
protein spots that may result in an inaccurate identification by mass spectrometry.  
 
4.4.9 Mass spectrometry (MS) 
            Protein spots were manually excised from the 2-DE gel and processed using a 
MassPrep II Proteomics Workstation (Micromass, UK) following the procedure described by 
Sheoran et al (196). Briefly, gel bands are destained twice (10 minute incubations) with 100 
µL of 1:1(v/v) ammonium bicarbonate:acetonitrile.  Protein reduction is performed with the 
addition of 10 mM DTT prepared in 0.1M ammonium bicarbonate.  Gels are washed and 
dehydrated before being saturated with trypsin and prepared in ammonium bicarbonate. 
Digestion was carried out at 37ºC.  Peptides were extracted with 30 µL 0.1% trifluoroacetic 
acid/3% acetonitrile, and then twice with 24 µL, 0.1% trifluoroacetic acid/50% acetonitrile.  
The combined extracts were dried in a speed vac (Labconco, Fishier 
Scientific, Waltham, MA, USA ).  Samples were reconstituted in 40 µL of 0.1% 
trifluoroacetic acid/3% acetonitrile for LC-ESI MS analysis. For LC-ESI MS analysis, 2 μL 
of the solution was used. LC/MS/MS was performed on Quadrupole Time-Of-Flight (Q-TOF) 
Global Ultima mass spectrometer (Micromass, Manchester, UK) equipped with a nano-
electrospray (ESI) source and interfaced with a nanoACQUITY UPLC solvent delivery 
system (Waters, Milford, MA, USA). Resulting values from analysis were used to search 
against the NCBInr and Swiss-Prot databases for Rattus norvegicus. We used the MASCOT 
(version 2.4, www.matrixscience.com) search engine to search the protein database and 
identify the protein. For MS/MS ions search we assumed: 1) incomplete protein digestion by 
trypsin (1 missed cleavage level). Also thresholds of analysis ±50 ppm (fraction expressed as 
parts per million) and ±200 mmu (absolute milli-mass units) error windows on experimental 
peptide mass and for fragment mass tolerance were used. Mandatory alkylation and reduction 
of cysteines with iodoacteamide, and variable oxidation of methionine were assumed.  
Mowse scoring algorithm (197) was used to justify accuracy of protein identification, which 
is incorporated in the MASCOT search engine. The Mowse score is the probability that the 
observed match is a random event, and is presented as -10*log10(P) where P is the absolute 
probability. 
 
4.4.10 Measurement of ATP synthase activity 
            ATP synthase activity was determined using a commercially available ATP synthase 
assay kit (Abcam, Cambridge, MA, USA) according to the supplier’s instructions. This assay 
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determines the activity of ATP synthase in a human or rat sample. Briefly, the ATP synthase is 
immunocaptured and the enzyme activity is measured by monitoring the decrease in 
absorbance at 340 nm, which is caused by the conversion of ATP to ADP by ATP synthase. 
This conversion is coupled with oxidation of NADH to NAD+ which is associated with 
reduction in absorbance at 340 nm. 
 
4.4.11 Subunit beta of ATP synthase and MMP-2 sequence analysis 
            With the use of LALING peptide sequence comparison program 
(http://www.ch.embnet.org/software/LALIGN_form.html), the primary sequence of rat 
mitochondrial ATP synthase subunit beta (accession # P10719) for UniProtKB/Swiss-Prot 
protein Knowledgebase) was compared with 14 known MMP-2 cleavage recognition sites 
(10 amino acids each) (192). Sites that had a >60% homology for all 10 amino acids were 
considered in this analysis. 
 
4.4.12 Statistical analysis 
            The protein spot levels were analyzed using t-test and Mann–Whitney U-test, which is 
incorporated in the PDQuest measurement. The proteins of interest were identified by MS. 
ANOVA and Kruskal–Wallis test were used in functional studies. Data are expressed as the 
mean ± SEM. 
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4.5 Results 
 
4.5.1 The effect of siRNA transfection on cardiomyocyte viability and contractility 
            After 48 hours incubation the viability of control cardiomyocates was approximately 
60%.  Transfection of scrambled siRNA did not further decreased cell viability and was 
similar to the control level (Figure 4.2A).  Similarly, the contractility of cardiomyocytes 
transfected with scramble siRNA was comparable to the contractility of the control cells 
(Figure 4.2B). 
 
 
Figure  4.2 
Effect of siRNA transfection on cardiomyocytes viability (A) and contractility (B).  Results are 
presented as percentage of live cells and contractility is presented as percent of cell shortening.  
n=5/group; *p<0.05  
 
4.5.2 MMP-2 activity and MMP-2 expression in cardiomyocytes with MMP-2 
knockdown cells 
            Because control cardiomyocytes and cardiomyocytes transfected with scrambled 
siRNA did not differ in viability and contractility (Figure 4.2), in all experiments the cells 
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transfected with scrambled siRNA were used as a control to MMP-2 siRNA transfected cells.    
Efficiency of silencing of MMP-2 expression by MMP-2 siRNA transfection was 
evaluated by three different methods: gelatin zymography, immunoblot analysis, and confocal 
microscopy (Figure 4.3).  Total MMP-2 activity; determined by gelatin zymography, was 
reduced by approximately 70% in comparison to control cells (Figure 4.3A).  Similar 
decrease was observed when an MMP-2 protein level was determined by immunoblotting 
(Figure 4.3B).  The pro MMP-2 form (72 kDa) was almost no detectable in both techniques 
(Figure 4.3A and B).   Confocal microscopy showed that the level of MMP-2; evaluated by 
immunstaining, decreased by approximately 40% in the cardiomyocytes transfected with 
MMP-2 siRNA, in comparison to scramble siRNA transfection (Figure 4.3C).   
Transfection efficiency was determined by the measurement of fluorescence from 
GFP tagged siRNA which was co-transfected with either scramble or MMP-2 siRNA (Figure 
4.3C).  GFP fluorescence revealed that transfection efficiency was approximately 95% (data 
not shown).   
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Figure  4.3 
Inhibition of cardiomyocyte MMP-2 expression by MMP-2 siRNA.  (A) Analysis of MMP-2 activity by 
zymography.  (B) Analysis of protein level of MMP-2 by immunoblotting.  (C) Evaluation of transfection 
efficiency.   The efficiency was determined by measurement of fluorescence from GFP tagged siRNA 
which was co-transfected with MMP-2 siRNA or scrambled siRNA.  n=6-13/group; *p<0.05  
 
4.5.3 Effect of inhibition of MMP-2 expression on cardiomyocyte viability and 
contractility 
           Cardiomyocyte viability and contractility were measured after a total of 48 hours 
including stabilization, transfection and incubation periods.  Transfection of MMP-2 siRNA 
improved cell viability by approximately 15% (Figure 4.4A) and increased three fold 
cardiomyocyte contractility in comparison to the group of cells transfected with scrambled 
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siRNA (Figure 4.4B).   
 
Figure 4.4 
Effect of MMP-2 siRNA transfection on cardiomyocytes viability (A) and contractility (B).  Scramble 
siRNA was used as a control of MMP-2 siRNA.  Results are presented as percentage of live cells and 
contractility is presented as percent of cell shortening.  n=5/group; *p<0.05  
 
 
4.5.4 2-DE of protein extracts from siRNA transfected cells 
            Protein extracts from the scrambled and MMP-2 siRNA groups were separated by 2-
dimensional electrophoresis (2-DE) (Figure 4.5).  Analysis of the protein spot intensity 
variation (using an arbitrary threshold) detected 13 protein spots affected by inhibition of 
MMP-2.  Nine protein spots showed an increase (Figure 4.6A) and four protein spots showed 
a decrease following MMP-2 siRNA treatment (Figure 4.6B).    
The identification of these 13 protein spots is shown in Table 4.1.  Seven protein spots 
were identified as mitochondrial enzymes involved in energy production; 5 of these are 
significantly increased in the MMP-2 siRNA group and include ATP synthase beta unit, 
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dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase 
complex, cytochrome c oxidase subunit 5A, electron transfer flavoprotein subunit beta and 
NADH dehydrogenase (ubiquinon) 1 alpha subcomplex subunit 5.  Two of them are reduced 
and include ATP synthase beta subunit (cleaved form of full length molecule) and long-chain 
specific acyl-CoA dehydrogenase, mitochondrial precursor.  Two protein spots (245 and 237) 
were identified as the contractile protein myosin light chain 1 (MLC1) (see Table 4.1).  
Protein spot 245 was identified as intact MLC1 and was significantly higher in the MMP-2 
siRNA group (Figure 4.6A).  Spot 237 was identified as a truncated form of MLC1 and its 
level was approximately 2 fold lower in the MMP-2 siRNA group (Figure 4.6B).  Other 
protein spots were identified as heat shock protein 60 precursor and Cu-Zn superoxide 
dismutase.   
Because MLC1 is a substrate for MMP-2 (22, 89), and changes in its level in 
cardiomyocytes perfused with MMP-2 inhibitors are described (47), to validate results from 
2-DE we measured level of MLC1.  In addition to MLC1 levels measured in 2-DE, we 
evaluated its level by immunobloting.  The MLC1 level, similarly to the results from 2-DE, 
was increased (Figure 4.7) in immunoblotting as well.  Measurement of tubulin level was 
used as a control of protein loading. 
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Figure 4.5 
Two-dimensional electrophoresis (2-DE) of cardiomyocyte homogenates.  Representative gels of 2-
DE of protein extracts from control (scramble siRNA) group and MMP-2 siRNA group are showed.  
The arrows indicate protein spots significantly changed by MMP-2 inhibition.  n=6/group; *p<0.05  
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Figure  4.6 
Effect of MMP-2 siRNA transfection on cardiomyocyte proteome.  For better visual presentation, the 
altered proteins are grouped in three groups.  Each panel represents one protein group according to 
the level of abundance.    n=6/group *p<0.05 versus control group 
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Table 4.1 Identification of protein spots from control group VS MMP-2 siRNA group 
Exp, experimental 
Protein spot NO. 
(Accession 
NO.) 
Mowse 
score a 
Queries 
matched 
Sequen
ce 
covera
ge  
(%) 
pI(Exp)/MW(Exp)  
(kDa)  
Identified protein Fold  
change 
p value 
 
Energy 
production 
            
234 ↑ b 
(Q01205) 
765 16 31 8.89 (6.0)/49.236 (66) Dihydro- 
lipoyllysine-
residue 
succinyltrans-
ferase  component 
of 2-oxoglutarate 
dehydrogenase 
complex, 
mitochondrial 
1.6 0.042 
235 ↑ 
(P10719) 
1149 26 39 4.92(5.2)/ 51.171(38) ATP synthase beta 
subunit 
fragment 
1.4 0.016 
236 ↓ 
(P10719) 
1115 30 44 4.92 (4.2)/ 51.171(36) ATP synthase 
beta subunit 
fragment 
-1.9 0.033 
238 ↑ 
(P11240) 
389 11 34 6.08 (4.3)/16.347 (13) Cytochrome c 
oxidase subunit 
5A, mitochondrial 
precursor 
1.3 0.045 
239 ↓ 
(P45953) 
190 6 10 7.63 (5.2)/ 48.242 (15) Long-chain 
specific acyl-CoA 
dehydrogenase 
mitochondrial 
precursor 
-2.0 0.047 
243 ↑ 
(Q68FU3) 
 
 
1459 31 49 7.60 (8.4)/27.898 (36) Electron transfer 
flavoprotein 
subunit beta 
1.5 0.037 
244 ↑ 
(Q63362) 
1366 24 68 6.84 (7.1)/13.460 (10) NADH 
dehydrogenase 
[ubiquinone] 1 
alpha subcomplex 
subunit 5 
1.3 0.045 
Structural  
protein  
       
237 ↓ 
(P02600) 
293 
 
8 
 
40 5.03 (4.9)/ 22.256 (27)  Myosin light 
chain 1 
-1.9 0.006 
245 ↑ 
(P02600) 
219 6 18 5.03 (4.9)/ 22.256 (31) Myosin light 
chain 1 
1.3 0.033 
Others        
240 ↑ 
(CAA32441) 
116 8 26 5.42 (6.3)/15.856 (14) Unnamed protein 
product 
1.4 0.045 
232 ↑ 
(CAA37664) 
 
2261 47 69 5.35 (5.3)/58.06 (84) Unnamed protein 
product 
1.4 
 
 
0.020 
233 ↑ 
(P63039) 
1070 26 48 5.91 (5.9)/ 61.098 (78) Heat shock 
protein 60 
precursor 
1.8 0.025 
241 ↓ 
(P07632) 
338 8 32 5.88 (6.3)/ 15.871 (18) Cu-Zn superoxide 
dismutase 
-1.3 0.003 
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a) Ions score is -10*Log(P), where P is the probability that the observed match is a random 
event.  Individual ions scores > 31 indicate identity or extensive homology (p<0.05). 
b) The arrows (↑↓) indicate statistically significant changes in protein levels (versus control 
group) 
 
 
Figure 4.7 
Validation of 2-DE results by immunobloting.  Protein level of MLC1 was used to validate the results 
obtained by 2-DE.  Tubulin was used as a protein loading control.  n=5/group; *p<0.05  
 
 
4.5.5 ATP synthase protein level and its activity 
            The analysis of protein spot 235 and 236 showed that these protein spots represent 
two different molecular forms of beta subunit of ATP synthase (Figure 4.8A).  The level of 
the first protein spot (#235) was increased in MMP-2 siRNA group whereas the level of the 
second protein spot (#236) was decreased (Figure 4.8B)  
           Analysis of tryptic peptides identified by MS analysis (indicated in red in figure 4.9A) 
showed that the protein spot 235 represents the whole protein, whereas the second (spot 236) 
represents the truncated form of ATP synthase beta subunit with a lower molecular weight 
(Figure 4.9A).  Comparison of molecular sizes of both forms of beta subunit (Figure 4.8A) 
and amino acid sequences (Figure 4.9A) shows that spot 236 is smaller than spot 235 by 
approximately 5 kDa.   
Comparison of the ATP synthase beta subunit amino acid sequence with various MMP-
2 cleavage recognition sequences revealed one site of interest localized between threonine 
421 (T421) and leucine 430 (L430)  and is indicated by the green box in figure.  The site at 
amino acid 421 to 430 showed 60% homology to the MMP-2 cleavage consensus sequence 
(Figure 4.9B).  The sequence of amino acids in P1-P6 positions shows over 80% homology 
(Figure 4.9B).  In proteolytic enzyme research, the capital letters P and P’ describe 
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localization of amino acid residue in the cleavage site region.  The P amino acid residues are 
localized on left side of the cleavage site and P’ residues are localized on the right side.  The 
number indicates the location of the amino acid residue relative to the cleavage site.  In 
addition, a low abundant tryptic peptide FLSQPFQVAEVFTGHMGK localized between 
amino acids phenylalanine 408 (F408) and lysine 236 (K236) was found in spot 236 (this 
peptide is underlined in red in figure 4.9A).  The identified peptides and localization of 
cleavage site in the beta chain of ATP synthase by MMP-2 shows that the product of MMP-2 
action will be shorter by 48 amino acids (approximately 5kDa).  The localization of the 
recognized sequence by MMP-2 is shown in green in Figure 4.9A.   
         In addition to expression level, ATP synthase activity was evaluated using an ATP 
synthase enzyme activity assay.  In the MMP-2 siRNA group, ATP synthase activity was 
increased by approximately 30% (Figure 4.10).   
 
Figure  4.8 
Effect of MMP-2 inhibition on beta subunit of ATP synthase.  (A) Fragments of representative 2-DE 
gels from control (scramble siRNA) group and MMP-2 siRNA.  Arrows indicate protein spots of ATP 
synthase subunits beta.  (B) Densitometric analysis of affected protein spots.   n=6/group; *p<0.05 
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Figure  4.9 
(A) Analysis of tryptic digests of ATP synthase subunit beta.  The sequence coverage of beta subunit 
with experimentally obtained peptides is highlighted in red.   Cleavage site for MMP-2 is showed in 
green.  (B) Analysis for possible MMP-2 cleavage site within beta subunit of ATP synthase.  The red 
line shows the C-terminus peptide detected in truncated form of ATP synthase.  Amino acids of beta 
subunit was compared with various MMP-2 cleavage recognition sites.   Two dots denote the same 
amino acid whereas one dot denotes a similarity.  The letters P and P’ describe localization of amino 
acid residues in the cleavage site region.  The P amino acid residues are localized on left side of the 
cleavage site and P’ residues are localized on the right site.  The number indicates the location of the 
amino acid residue from to the cleavage site. 
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Figure  4.10 
Effect of MMP-2 siRNA transfection on activity of ATP synthase in cardiomyocytes.   n=6/group; 
*p<0.05  
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4.6 Discussion 
 
Ischemia /reperfusion (I/R) injury of the heart is a complex processes ranging from 
molecular to functional adaptations in response to ischemia and/or reperfusion. The 
contribution of each phenomenon to the development of lethal injury remains a matter of 
controversy  [reviewed in (198)]. 
In general, it is accepted that protein degradation within the heart is a major 
component of the regulatory mechanism in both the physiology and pathology of the heart. 
For decades it was commonly acknowledged that cardiac protein degradation was mediated 
by three main pathways such as the ubiquitin-proteasome pathway, autophagy/lysosomal 
degradation, and the calpain pathway (199). Research from the last decade shows that matrix 
metalloproteinase-2 (MMP-2) is another proteolytic enzyme involved in contractile 
dysfunction in I/R hearts [see review (101)]. In addition, it has been suggested that MMP-2 
can be involved in physiological regulation, such as regulation of normal turnover of cardiac 
proteins (46). Rate of protein turnover in heart tissue varies considerably. It has been 
estimated that about 30% of newly synthesized protein in the heart is degraded in a period of 
10 minutes. In the I/R heart, that period can be shorter (200). In a normal heart; in the case of 
sarcomeric proteins, the turnover is considered to be much slower, and is estimated to be 5-8 
days (201). 
Despite a large number of studies on the role of MMP-2 in heart injury, the 
physiological role of MMP-2 in regulation of cardiac contractility is still unclear. We have 
already shown that in I/R injury, MMP-2 degrades contractile proteins (22, 89). However, 
other mechanisms involving regulation of energy metabolism have been suggested (23, 202). 
Among a variety of work, including ours, it has been shown that contractile protein such as 
troponin I (114), myosin light chain 1 (MLC1) (22) and 2 (MLC2) (145), and titin (115) are 
degraded by MMP-2 during cardiac injury, and inhibition of MMP-2 shows cardioprotective 
effects mainly related to the protection of contractile proteins (203).  
All of these observations have been made in intact isolated hearts undergoing rapid 
injury processes (minutes) and appear to be independent of changes in collagen content (204-
205).  However, many cell types in the heart express MMP-2 activity, including vascular 
endothelial cells.  Therefore, it is possible that the MMP-2 from endothelial cells may have a 
paracrine effect on cardiac myocytes to effect changes in their contractility, or the MMP-2 
may have an autocrine effect on the same myocytes.  The use of isolated myocytes as a 
biological model should provide evidence whether the intracellular action of MMP-2 in a 
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single cell directly modulates protein level. This is why we decided to utilize a proteomic 
approach to investigate the cardiomyocyte protein profile affected by MMP-2 inhibition using 
isolated myocytes perfused under aerobic physiological conditions. 
There are a few approaches developed for inhibition of MMPs, however none of those 
is specific against MMP-2. To overcome this problem we decided to knockout MMP-2 
expression with small interfering RNA. Small interfering RNA (siRNA), also known as 
silencing RNA, is a class of double stranded RNA molecules, which can specifically inhibit 
protein synthesis by interfering with mRNA. In this study, we evaluated the effect of MMP-2 
siRNA transfection on cardiomyocyte contractility and proteomic profile.  
In our studies we inhibited near complete synthesis of the pro-form of MMP-2 (72 
kDa) with siRNA. This inhibition is indicated by lack of the 72 kDa form in zymography and 
immunoblot analysis. The detection of the 64 kDa form of MMP-2 in both techniques is due 
to the nature of the activation process of MMP-2, which occurs on the surface of cell 
membranes (206-208).  The cell surface MMP-2 is not accountable for degradation of 
intracellular proteins. The surface cell distribution of MMP-2 in MMP-2 siRNA transfected 
cells is visible by immunocytochemistry with confocal microscopy. 
In the present study we observed that the contractility of cardiomyocytes is 
significantly higher in the myocytes transfected with MMP-2 siRNA in comparison to the 
control group.  The damaging role of MMP-2 in a heart subjected to oxidative stress is 
already established [reviewed in (209-210)]. Additionally, the role of MMP-2 in normal heart 
physiology has also been postulated (210). Based on the postulated role of MMP-2 in normal 
heart physiology we hypothesize that MMP-2 regulates turnover of sarcomeric proteins. The 
increased level of intact form of MLC1 and decreased level of truncated form of MLC1 in 
MMP-2 siRNA transfected cells were expected as previously reported (5,20, 21).  The 
changes in the levels of both forms of MLC1 in MMP-2 siRNA group resembled those 
changes observed with pharmacological inhibition of MMP-2.  Therefore the changes in 
MLC1 levels (intact or truncated form) were a good control of our experimental design to 
study MMP-2 activity in the isolated cardiomyocytes.  
We have found that the inhibition of MMP-2 expression affected the levels of 6 
proteins involved in energy metabolism. It has already been shown that MMP-2 accumulates 
in cardiac mitochondria and that increased MMP-2 activity is associated with mitochondrial 
dysfunction (211). Changes in the level of subunits of mitochondrial ATP synthase in heart 
injury were previously reported in several models of heart injury (176, 202, 212).  It has also 
been suggested that inhibition of Rho kinase with Y-27632 normalizes the level of ATP 
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synthase in I/R hearts (23). Despite these previous reports, however, speculation pertaining to 
the precise mechanism responsible for this normalization is lacking.  For the first time, our 
results show that the mitochondrial dysfunction caused by MMP-2 might depend on 
metabolic enzyme regulation, including the ATP synthase.  
To explore the effect of MMP-2 on energy production in cardiomyocytes, we focused 
on ATP synthase. Two molecular forms of subunit beta of ATP synthase were affected by 
inhibition of MMP-2. Peptide analyses of the beta subunit of ATP synthase, showed increased 
levels with MMP-2 siRNA and this form likely represented the full length protein. We also 
observed a beta subunit of ATP synthase with decreased levels after MMP-2 siRNA, which 
likely represented the truncated form with lower molecular weight and more acidic pI.  In 
support of this notion, examination of the amino acid sequence of beta subunit ATP synthase 
revealed an MMP-2 consensus cleavage site that gives rise to a 5kDa peptide fragment and 
the truncated ATP synthase. The negative effect of MMP-2 on ATP synthase is additionally 
supported by the fact that ATP synthase activity in cardiomyocytes with inhibited MMP-2 
expression is increased. Taken together, our present results implicate MMP-2 as a  significant 
contributor to the degradation of beta subunit of ATP synthase and, therefore, regulates the 
ATP synthase activity. However, more studies are needed to study the role of MMP-2 in 
mitochondrial dysfunction.  
Heat shock protein 60 (HSP 60) levels were also increased when MMP-2 expression 
was inhibited. The heat shock protein family are proteins that aid in protein folding and are 
involved in protein-protein interactions. If MMP-2 degrades HSP 60, the proper folding and 
functional expression of proteins may lead to alterations in cardiomyocyte function,  for 
instance, by decreasing  contractility (from MLC1 degradation) or by increasing 
mitochondrial dysfunction (from ATP synthase degradation) .  Additional experiments 
focused on HSP 60 are necessary to determine a possible role of MMP-2-HSP 60 pathway in 
myocyte damage. 
The decrease of Cu-Zn superoxide dismutase (171) level in MMP-2 knockout cells 
has no simple explanation, however it has been shown that over-expression of SOD is 
associated with activation of MMP-2 (213). Similar to HSP 60, more studies are needed to 
elucidate the role of MMP-2 in regulating SOD expression and activity. 
In summary, this is the first report which shows that intracellular inhibition of MMP-2 
in cardiomyocytes increases contractility of aerobically perfused myocytes. In addition, we 
showed for the first time that this inhibition is also associated with increased activity of ATP 
synthase. An association of ATP synthase with MMP was already indicated in studies on 
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regulation of ATPase activity of transglutaminase 2 by MT1-MMP (214). We also show that 
changes in metabolic enzyme levels are likely associated with proteolytic processing by 
MMP-2.  The unanswered question is how this degradation/processing is regulated under 
physiological conditions? It is well established that phosphorylation is an important 
mechanism of regulation of energy metabolism (215). We have also shown that post-
translational modifications (PTMs) such as nitration, nitrosylation and phosphorylation 
regulate MMP-2 activity under pathological conditions (145). We expect that similar 
processes may provide a basis for regulatory mechanisms under physiological conditions.  
In conclusion, it appears that enzymes involved in energy production, including ATP 
synthase, are additional intracellular substrates for MMP-2. Thus, regulation of energy 
metabolism can be additionally achieved by modulation of intracellular action of MMP-2.  
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5.1 Preface 
 
         This manuscript has been published in the journal Biomed research international (Lin et 
al. 2014). This manuscript addressed the last objective of my PhD project. 
       5. To determine the cardioprotective effect of inhibition of MMP-2 using MMP-2 
siRNA on isolated cardiomyocytes. 
       From our studies, we conclude that MMP-2 degrades not only contractile proteins but 
also energy metabolic proteins, and this could be the key event of the development of 
ischemia/reperfusion injury. Developing a strategy for inhibition of MMP-2 may be a key 
therapy for ischemia/reperfusion injury. However, lack of selective MMP-2 inhibitor is the 
main barrier. Therefore, we decided to specifically inhibit MMP-2 by using MMP-2 siRNA, 
and we found that the inhibition of expression of MMP-2 protects cardiomyocytes from 
contractile dysfunction after ischemia/reperfusion. The key points of this study are: 1) prove 
again that MMP-2 plays a vital role in degradation of contractile and metabolic protein in 
ischemia/reperfusion injury; 2) develop a effective strategy for inhibition of MMP-2 by using 
MMP-2 siRNA to knockdown the expression of MMP-2; 3) this is the first study directly 
indicates the intracellular function of MMP-2, which is involve in contractile dysfunction in 
cardiomyocytes subjected to ischemia/reperfusion. 
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5.2 A bstract 
 
           Matrix metalloproteinases (MMPs) significantly contribute to ischemia reperfusion 
(I/R) injury, namely by the degradation of contractile proteins. However, due to the 
experimental models adopted and the lack of isoform specificity of MMP inhibitors, the 
cellular source and the identity of the MMP(s) involved in I/R injury remain to be elucidated. 
Using isolated adult rat cardiomyocytes, subjected to chemically induced I/R-like injury, we 
show that the specific inhibition of MMP-2 expression and activity by MMP-2 siRNA 
significantly protected cardiomyocyte contractility from I/R, associated with increased 
myosin light chains 1 and 2 (MLC1/2) expression levels, in comparison to scramble siRNA 
transfection. Moreover, the positive effect of MMP-2 siRNA transfection on cardiomyocyte 
contractility and MLC1/2 expression levels was also observed in the control group, 
suggesting an important additional role for MMP-2 in physiological sarcomeric protein 
turnover. 
           This study clearly demonstrates that autocrine intracellular expression of MMP-2 plays 
a significant role in sarcomeric protein turnover, namely MLC1 and MLC2, under aerobic 
(physiological) conditions. In addition, this study identifies intracellular/autocrine, 
cardiomyocyte-produced MMP-2, rather than paracrine/extracellular, as responsible for the 
degradation of MLC1/2 and consequent contractile dysfunction in cardiomyocytes subjected 
to I/R injury. 
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5.3 Introduction 
 
      The pathological role of matrix metalloproteinases (MMPs), including MMP-2, during 
the development of oxidative stress-mediated cardiac injury and contractile dysfunction has 
been shown previously (189, 191, 216). We and others have shown increased activity of 
MMP-2 in ischemic reperfusion (I/R) injury (127, 217-218), hypoxia-reoxygenation injury 
(219) and infusion of reactive oxygen species, namely peroxynitrite (ONOO-) (125, 128). 
Furthermore, increased intracellular MMP-2 activity (22, 114-115, 145) is associated with 
degradation of contractile proteins such as troponin I (114), titin (115), myosin light chain 1 
(MLC1)(22, 46, 89) and myosin light chain 2 (MLC2) (145). All these observations have 
been made in intact, isolated hearts during a relatively short time-course (minutes) and appear 
to be independent of changes in collagen content (204-205), suggesting preponderant acute 
intracellular action of MMP-2. 
     MMP-2 can be found in most cardiac cell types, including vascular endothelial cells 
(220), smooth muscle cells (221), fibroblasts (222) and cardiomyocytes (47, 114). The 
majority of MMP-2 synthesized is secreted (~60%) acting in a paracrine manner; with the 
remaining 40% being targeted to the cytosol (223) or mitochondrial associated membranes 
(224). Therefore, it is probable that MMP-2 originated in endothelium, smooth muscle cells 
or fibroblasts can be upregulated in response to oxidative stress and acting in a paracrine 
manner on cardiomyocytes, aiding in the development of I/R injury and cardiac contractile 
dysfunction. Hence, the understanding of MMP-2’s mechanism of action (paracrine vs. 
autocrine) and determination of the cellular source/targets of MMP-2 is crucial in the 
development of novel and more selective drug design.  
Greater than 20 MMPs have been described to date with all of them showing similarities in 
substrate specificities and response to known MMP inhibitors (225) limiting the clinical 
application of these broad-spectra drugs. The vast majority of studies, looking at the roles of 
MMPs in the development of I/R injury, have been performed in whole heart or whole 
cardiac tissue homogenates, without the discrimination between cell types. Moreover, the 
pharmacological approaches used to modulate MMPs’ activity rely on the use of broad 
spectra MMP inhibitors (eg. doxycyline, ortho-phenathroline) not being possible to clearly 
identify isoform specific effects. Inhibition of MMP-2 has been shown to protect isolated 
cardiomyocyte contractility in response to oxidative stress (47, 226). Nonetheless, clinical 
usage of subantimicrobial doses of doxycyline in patients undergoing cardiopulmonary 
bypass surgery failed to show a protective effect on cardiac function despite the inhibition of 
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MMP-2 (227). Consequently, despite the wide body of pre-clinical evidence supporting 
inhibition of MMP-2 in cardiac pathologies, the failure of clinical translation makes it crucial 
to determine the physiological and pathological roles of MMP-2 to properly develop 
therapeutic strategies targeting MMP-2.  
    Here we unequivocally show that specific, autocrine, intracellular action of MMP-2 on 
cardiomyocytes regulates not only contractile protein turnover under physiological conditions 
but also the development of I/R-induced cardiac contractile dysfunction, via increased 
degradation of contractile proteins. These observations, made with the use of a specific 
inhibition of MMP-2 with siRNA, provide novel and important knowledge on the role of 
MMP-2 in I/R injury and indicate potential therapeutic alternatives to the prevention and 
treatment of I/R injury. 
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5.4 Materials and methods 
 
            This investigation conforms with the Guide to the Care and Use of Experimental 
Animals published by the Canadian Council on Animal Care. 
 
5.4.1 Cardiomyocyte isolation 
            Male Sprague-Dawley rats (weighing 100–150 g) were anaesthetized with sodium 
pentobarbital (60 mg/kg i.p.) and hearts were removed. Right ventricular myocytes were used 
as they provide a consistently higher ratio of live cardiomyocytes to contaminating fibroblasts 
and endothelial cells in comparison to preparations from the left ventricle (191). Right 
ventricular myocytes were obtained by enzymatic dissociation as previously described (194). 
 
5.4.2 Primary culture of cardiomyocytes 
            Isolated cardiomyocytes were seeded in 35x10 mm cell culture plates (Nunc, Roskilde, 
Denmark) at 2×105 cells per plate in DMEM medium (Lonza Walkersville, MD USA) 
supplemented with 10% FBS and incubated in a 95% air-5% CO2 incubator at 37°C for 7 
hours to stabilize cells. Viability and contractility of the isolated cardiomyocytes were 
assessed after isolation, transfection with siRNA and at the end of reperfusion (Figure 5.1). 
 
Figure 5.1 
Schematic representation of the perfusion protocol for isolated cardiomyocytes. Scrambled siRNA 
was used as a control of MMP-2 siRNA. Arrows indicate when cell contractility was measured: (1) 
before siRNA transfection, (2) before ischemia, (1) at the end of reperfusion. 
 
 
5.4.3 siRNA transfection 
              A mixture containing a pool of 3 target-specific 19-25 nucleotide small interfering 
RNAs (MMP-2 siRNA) designed to knock down rat MMP-2 gene expression (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) was resuspended in RNAse-free water to a final 10 
μM stock concentration in a buffer containing 10 μM Tris-HCl, 20 mM NaCl, and 1 mM 
EDTA at pH 8.0. This solution was stored at -20°C. As a control, scrambled siRNA (Santa 
Control 
MMP-2 siRNA 
Measurement of viability and contractility cells 
Scramble siRNA transfection (24h) Ischemia (3min) 
MMP-2 siRNA transfection (24h) Ischemia (3min) 
Reperfusion (20 min) 
Reperfusion (20 min) 
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Cruz Biotechnology, Santa Cruz, CA, USA) was used under the same conditions. 
       Following a 7 hour stabilization period in DMEM and 10% FBS, cardiomyocytes 
were washed with siRNA transfection medium (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) and incubated for 24 hours at 37°C in 200μL of transfection medium containing 0.8 
μM of MMP-2 siRNA or scrambled siRNA (Figure 1) according to the manufacturer’s 
protocol. For assessment of transfection efficiency, green fluorescent protein (GFP) was co-
transfected with siRNA.  
 
5.4.4 Simulated ischemia/reperfusion protocol 
            After 24 hours of transfection with siRNA, cardiomyocytes were subjected to 
chemical ischemia, as previously described (228). Briefly, the transfection medium was 
removed and replaced with a solution containing 5mM 2-deoxyglucose to inhibit glycolysis 
and 4 mM NaCN to inhibit mitochondrial respiration (ischemia). After 1, 3, 5 and 7 minutes 
of incubation the solution was removed and replaced with culture medium without FBS 
(reperfusion).   
 
5.4.5 Measurement of viability and contractility of cardiomyocytes 
            Cardiomyocyte viability and contractility were evaluated at three time points 
throughout the experimental protocol: after cell isolation, after transfection with siRNA 
(before ischemia), and at the end of reperfusion (Figure 1). The viability of cardiomyocytes 
was assessed by the trypan blue exclusion test (229-231). Cardiomyocyte contractility was 
measured using IonOptix system and the IonWizard 6.0 software (IonOptix, Milton, MA 
USA). After a stabilization period the chamber containing the cells was perfused with an 
oxygenated buffer at a constant temperature of 37°C. Cells were continuously paced at 1 Hz 
and 5 V (IonOptix MyoPacer, Milton, MA, USA). The assessment of cardiomyocyte 
contractility was made by the measurement of peak shortening, maximal velocity of cell 
shortening and maximal velocity of cell relengthening (47) on 8-10 cardiomyocytes per 
independent experiment,  over a 10 min period to give an average measure per sample. 
 
5.4.6 Preparation of cell extracts 
             Cardiomyocytes were collected and stored at -80°C. For biochemical studies, frozen 
cardiomyocytes were thawed and sonicated on ice twice for 5 seconds in 50 mM Tris-HCl 
buffer (pH 7.4) containing 3.1 mM sucrose, 1 mM DTT, 10 μg/mL leupeptin, 10 μg/mL 
soybean trypsin inhibitor, 2 μg/mL aprotinin, and 0.1% Triton X-100. Homogenates were 
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then centrifuged at 10000g at 4°C for 10 minutes and the supernatant was collected and 
stored at -80°C until further use. Protein content of the cardiomyocyte extract was measured 
using the Bradford protein assay (Bio-Rad, Hercules, CA, USA). 
          
5.4.7 Measurement of MMP-2 activity 
            Gelatin zymography was performed as previously described (122, 127, 166). Briefly, 
homogenates from cardiomyocyte preparations containing 30 μg of protein were applied to 
8% polyacrylamide gel copolymerized with 2 mg/mL gelatin. After electrophoresis, gels were 
rinsed three times for 20 minutes in 2.5% Triton X-100 to remove SDS. The gels were then 
washed twice in incubation buffer (50 mM Tris-HCl, 5 mM CaCl2, 150 mM NaCl and 0.05% 
NaN3) for 20 minutes at room temperature and incubated in incubation buffer at 37°C for 24 
hours. The gels were stained using 0.05% Coomassie Brilliant Blue G-250 in a mixture of 
methanol:acetic acid:water (2.5:1:6.5, v:v:v) and destained in aqueous solution of 4% 
methanol:8% acetic acid (v:v). Developed gels were scanned with an GS-800 calibrated 
densitometer and MMP-2 activity was measured using Quantity One 4.6 software (Bio-Rad, 
Hercules, CA, USA). 
 
5.4.8 Western blot analysis 
            Protein (30 µg) from cardiomyocyte homogenates were separated using 12% SDS-
PAGE and transferred to a PVDF membrane (Bio-Rad, Hercules, CA, USA). Myosin light 
chain 1 and 2 (MLC 1 and MLC2) were identified using mouse monoclonal anti-MLC1 
antibody and rabbit polyclonal anti-MLC2 antibody, respectively (Abcam, Cambridge, MA, 
USA), MMP-2 was identified using rabbit monoclonal anti-MMP-2 antibody (Abcam, 
Cambridge, MA, USA). Membranes were developed using Versa Doc 5000 and band 
densities were measured with Quantity One 4.6 software (Bio-Rad, Hercules, CA, USA). 
Equal protein loading was additionally verified by measurement of tubulin level with mouse 
monoclonal antibody (Abcam, Cambridge, MA, USA). 
 
5.4.9 Immunocytochemistry 
            For immunocytochemistry, cardiomyocytes were seeded on polylysine-coated 
coverslips and follow the same siRNA transfection protocol. After permeabilization with 
0.25% Triton X-100 and fixation, cells were blocked for 1 h with PBS containing 5% bovine 
serum albumin (BSA, Sigma, St Louis, MO, USA). Proteins of cardiomyocytes were labeled 
by overnight incubation (at 4°C) with rabbit anti-MMP-2 (Abcam, Cambridge, MA, USA) 
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antibody diluted at 1:200 in blocking buffer followed by brief wash (three times; 10 min each) 
and incubation with Alexa Fluor 555-conjugated goat anti-rabbit secondary antibodies 
(Invitrogen, Carlsbad, CA, USA) at 1:1000 for 1 h. After Hoechst (Sigma, St Louis, MO, 
USA) staining, the coverslips were mounted on newly cleaned slides using Prolong Gold 
Antifade Reagent (Invitrogen, Carlsbad, CA, USA) and observed with an LSM700 laser 
scanning confocal microscope (Carl Zeiss, Oberkochen, Germany). Images were acquired 
using a Zeiss Plan-Apochromat 63X/1.6 oil objective lens and analyzed with the Zeiss Zen 
2009 software (version 5.5 SPI).  
 
5.4.10 Immunoprecipitation 
            The immunoprecipitation of MMP-2 with MLC1 or MLC2 was initiated by 
incubating 200 µg of total protein extract with 10 µg mouse anti-MLC1 IgG or 10 µg rabbit 
anti-MLC2 IgG in a total volume of 500 µl RIPA buffer (150 mM NaCl, 1% IGEPAL CA-
630, 0.5% sodium deoxycholate (DOC), 0.1% SDS, 50 mM Tris, pH 8.0, 1 mM PMSF) 
overnight at 4 °C.  This buffer was chosen because of its known high stringency to avoid 
unspecific binding.  As a negative control, unrelated IgG was used instead of anti-MLC IgG.  
Following the initial incubation, 100 µl of slurry of protein A–Sepharose beads were added 
and the resulting mixture incubated overnight at 4 °C.  After overnight incubation the mixture 
was washed three times with 0.5 ml of RIPA buffer at 4 °C and 20 µl of sample buffer were 
added.  Determination of co-localization of MLC1 or MLC2 with MMP-2 was determined by 
gelatin zymography of the immunoprecipitates. 
 
5.4.11 Statistical analysis 
            For contractility measurements, at least three independent experiments (myocyte 
preparations from different hearts) were run. Each experiment was performed in triplicate 
(myocytes from the same heart). ANOVA with Kruskal–Wallis post-hoc analysis or Student’s 
t-tests were used in this study. A P < 0.05 indicated statistical significance. Data are presented 
as the mean ± SEM. 
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5.5 Results 
 
5.5.1 Cell contractility and duration of ischemia 
            The effect of the duration of ischemia on cardiomyocyte viability and contractility 
was determined. One minute of ischemia decreased cardiomyocyte viability by 
approximately 10%, in comparison to aerobic control cells, with longer durations reducing 
viability further (Figure 5.2A). Cardiomyocyte contractility, namely peak shortening and 
maximal velocity of myocyte relengthening, was decreased after 1 minute of ischemia; 
however maximal velocity of myocyte shortening was unaffected (Figure 5.2B).  Three 
minutes of ischemia reduced contractility by 50% in all three measured parameters. Longer 
periods of ischemia (5 and 7 min) further reduced contractility to approximately 70-80% of 
aerobic values (Figure 5.2B). Based on cellular viability and contractility, 3 minutes of 
ischemia was chosen for further experiments. 
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Figure 5.2 
Effect of the duration of ischemia on cardiomyocyte viability (A) and contractility (B). The mean total 
number of alive cardiomyocytes in the control group is considered as 100%.  n= 3-4 heart 
preparations per group, *p<0.05 versus aerobic control. 
 
5.5.2 MMP-2 expression and activity in cardiomyocytes transfected with MMP-2 
siRNA 
      MMP-2 siRNA transfection silencing of expression was evaluated by gelatin 
zymography, immunoblot analysis, and immunocytochemistry using confocal microscopy 
(Figure 5.3). 
      Transfection efficiency, determined by the measurement of GFP-tagged siRNA 
fluorescence that was co-transfected with either scrambled or MMP-2 siRNA (Figure 5.3A, 
top pannel), was approximately 95%. This efficiency of overall transfection was associated 
with a 50 % decrease in the levels of MMP-2, evaluated by immunocytochemistry, in 
cardiomyocytes transfected with MMP-2 siRNA, in comparison to control cells transfected 
with scramble siRNA (Figure 5.3A).  
      Total MMP-2 activity, as determined by gelatin zymography, was reduced by 
approximately 70% in comparison to control cells transfected with scrambled siRNA (Figure 
3B). Although the cleaved 64 kDa form of MMP-2 was detected after knocking down MMP-
2 mRNA, the pro MMP-2 form (72 kDa) was undetectable (Figure 5.3B). A similar decrease 
was observed for MMP-2 protein level determined by immunoblotting (Figure 5.3C).    
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Figure 5.3 
Effect of MMP-2 siRNA transfection on MMP-2 expression in isolated cardiomyocytes. (A) Efficiency 
of siRNA transfection and MMP-2 protein levels measured by immunocytochemistry. Scale bar, 50 μm. 
(B) Measurement of MMP-2 gelatinolytic activity by zymography. (C) MMP-2 protein level. (A) n=25 
cells from 3 different hearts per group; n= 9-10 heart isolates per group for MMP-2 activity (B), in (C) 
n=4 heart isolates per group, and in , *p<0.05 versus aerobic control. 
 
5.5.3 MMP-2 knockdown effects on cardiomyocyte contractility before and after I/R 
injury 
             The effect of siRNA transfection on cell viability and contractility was evaluated using 
scrambled siRNA to control for possible effects independent of inhibition of MMP-2.  
Transfection of scrambled siRNA (control) did not impact either cardiomyocyte viability 
(Figure 5.4A) or contractility (Figure 5.4B). 
            Transfection of cardiomyocytes with MMP-2 siRNA resulted in an increase in the 
levels of the sarcomeric proteins myosin light chain 1 and myosin light chain 2 (MLC1 and 
MLC2, respectively) in comparison to control (Figure 5.5A). This increase in MLC1 and 
MLC2 was accompanied by a decrease in the formation of the protein complexes MMP-2–
MLC1 and MMP-2–MLC2 (Figure 5.5B). These observations at the protein level were 
associated with an increase in contractile function of aerobically perfused, MMP-2 siRNA 
transfected cardiomyocytes (before ischemia) in comparison to cells transfected with 
scrambled siRNA (Figure 5.5C).  
          The contractile function of cardiomyocytes, transfected with scrambled siRNA, in 
response to I/R was significantly decreased, whereas transfection with MMP-2 siRNA fully 
protected contractile function against I/R (Figure 5.6A). However, it should be noted that 
baseline contractility was higher in the MMP-2 knockdown cells than those with scrambled 
transfection (Figure 5.5). The protective effects of MMP-2 inhibition by siRNA transfection 
were associated with levels of MLC1 and MLC2 that were 3 and 2 fold higher, respectively, 
in comparison to control scramble siRNA transfected cells under aerobic conditions (Figure 
5.6B). 
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Figure 5.4 
Effect of scrambled siRNA transfection on cardiomyocyte viability (A) and contractility (B). Control 
cells were transfected with scrambled siRNA. n=4 heart isolations per group. 
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Figure 5.5 
Effect of MMP-2 siRNA transfection on the level of the contractile proteins MLC1 and MLC2 (A), the 
formation of the complex between MMP-2 and MLC1 or MLC2 (B) and cardiomyocyte contractility (C). 
As a protein loading control the tubulin level was measured. Control cells were transfected with 
scrambled siRNA. n=4-6 heart preparation isolations per group. n=11 per group for contractility 
measurement and n=4-6 for measurement of protein levels. *p<0.05 versus Control  
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Figure 5.6 
Effect of MMP-2 siRNA transfection on cardiomyocyte contractility (A) and MLC1 and MLC2 in 
cardiomyocytes subjected to I/R. As a protein loading control the tubulin level was measured. Control 
cells were transfected with scrambled siRNA. n=11 per group for contractility measurement and n=4 
for measurement of protein levels. *p<0.05 versus Control, #p<0.05 versus I/R. 
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5.6 Discussion 
 
            While the cellular mechanisms of I/R injury are complex and not entirely understood, 
the degradation of contractile proteins is considered to be a major cause of heart injury (22, 
232), with matrix metalloproteinase-2 (MMP-2) playing a significant role in contractile 
protein degradation (22, 114, 127, 145).  To the best of our knowledge, this study is the first 
to demonstrate that, under physiological conditions, MMP-2 regulates MLC1 and MLC2 
protein turnover. In response to I/R MMP-2 activity increases leading to degradation of these 
contractile proteins and decreased cardiomyocyte contractility. Inhibition of MMP-2 by 
siRNA transfection and reduction in protein levels protects MLC1, MLC2 and cardiomyocyte 
contractility from I/R. Moreover, our study clearly demonstrates that MMP-2 acts in an 
autocrine and intracellular fashion to regulate contractile protein turnover under physiological 
conditions or mediate I/R-induced injury. Furthermore, our study suggests that, in contrast to 
broad spectra MMP inhibitors, the use of MMP-2 siRNA to specifically modulate MMP-2 
activity can be of clinical relevance in the prevention and treatment of I/R injury and 
contractile dysfunction associated with loss of contractile proteins. 
       MMPs are proteolytic enzymes which are known to play a role in maintaining the 
structural integrity of the extracellular matrix (233).  However, studies over the last decade 
strongly suggest that MMP-2, in addition to the role in remodeling and degradation of 
extracellular matrix, is also involved in increased intracellular degradation of contractile 
proteins in heart subjected to oxidative stress (191, 234-235). This increased degradation 
reduces sarcomeric integrity resulting in contractile dysfunction of the injured heart (89).  
The study of the roles of MMP-2 in the heart has, almost exclusively, focused on pathological 
conditions. We have previously reported that MMP-2 may be involved in the physiological 
regulation of contractile proteins, namely MLC1 and MLC2 (46, 145). Here we show that the 
specific inhibition of MMP-2 protein levels and activity, in cardiomyocytes, with siRNA 
reduces the formation of the protein complex between MMP-2 and MLC1/2, resulting in an 
increase in MLC1/2 protein levels, in cells cultured under aerobic conditions. Importantly, the 
increase in MLC1/2 protein levels is associated with increased cardiomyocyte contractility. 
This observation suggests that inhibition of MMP-2 can potentially be a useful strategy to 
increase cardiac contractility in cardiac pathologies characterized by depressed cardiac 
function, such as heart failure (236). 
      Biological studies of specific MMP actions, including MMP-2, have been challenging 
due to the lack of selectivity and specificity of commercially available synthetic inhibitors. 
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Synthetic inhibitors of MMPs exhibit a broad spectrum of action across MMP families, with 
Ki in the nM range (237). The lack of selectivity and specificity are also evident by cross 
reactivity with other proteinases with distinct catalytic mechanisms from MMPs. Another 
drawback associated with synthetic inhibitors is toxicity. In fact cytotoxicity is a major 
limitation and is observed with the currently available MMP inhibiting drugs when higher 
doses are used (127, 238). The better alternative to a synthetic inhibitor could be the use of 
natural endogenous tissue inhibitors of MMP (TIMPs). However, despite having no 
interaction with other proteinases with different mechanism of action, they show poor 
selective within the MMP group (239). Moreover, genetic knockdown of MMP-2 has failed 
to provide an ubiquitously adequate model for the study of both the physiological and the 
pathological roles of MMP-2, since compensatory mechanisms have been observed to occur. 
For instance, a study on autoimmune encephalomyelitis it has been shown that MMP-2 KO 
mice exhibit a more severe disease than did their wild-type counterparts, that can be 
explained by a 3-fold increase in expression of MMP-9 (240) (an inducible MMP belonging 
to same group as MMP-2 (233)). With this in mind we decided to modulate MMP-2 activity 
by the use of small interfering RNA (siRNA). This genetic manipulation causes only a 
transient, but significant, reduction in MMP-2 protein expression and consequent overall 
enzymatic activity (Figure 3), minimizing the role of compensatory mechanisms that are 
usually triggered in germline knockouts as early as embryogenesis (241-242).  
      Small interfering RNA has proven to be an effective method for reducing gene 
expression through the use of a small piece of anti-sense RNA complementary to a gene of 
interest (243). In addition, siRNA has been successfully used in pre-clinical studies focused 
on cardiac tissue protection (244-245). By using MMP-2 siRNA we show that selective 
inhibition of intracellular MMP-2 protects the levels of myosin light chain 1 and 2 (MLC1/2) 
and contractility of cardiomyocytes subjected to I/R. Also, we show that the autocrine and 
intracellular actions of MMP-2 are responsible for contractile dysfunction and MLC1 
degradation in I/R injured cardiomyocytes, independent from paracrine and extracellular 
MMP-2 actions since no other cell types are present. Although we cannot exclude the 
involvement of other proteolytic enzymes or non-proteolytic pathways in regulating 
sarcomere contractility and protein turnover, we believe that the observed effects result solely 
from MMP-2 selective silencing, without the enabling of adaptive mechanisms. 
       In summary, this study provides clear evidence that intracellular MMP-2 plays a 
crucial role in the heart under both physiological and pathological conditions, namely at the 
level of regulation of contraction. The separation of intracellular from extracellular roles of 
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MMP-2 has the potential to provide new directions for studying mechanisms underlying 
several cardiac pathologies, including heart failure. Furthermore, due to the potential for the 
use of siRNA therapies in clinical practice, these results can have a significant impact on the 
development of new approaches for the protection of hearts from reperfusion injury due to 
myocardial infarction or coronary revascularization. 
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6. GENERAL DISCUSSION 
           The epidemic of cardiovascular diseases is one of the main burdens to society. Two 
thirds of cardiovascular diseases are related to coronary heart disease. The narrowing or 
blockage of the coronary arteries causes ischemia/reperfusion followed by myocardium 
infarction and contractile dysfunction, which eventually leads to heart failure. During I/R, it 
has been shown that many factors such as ROS(246), proteolytic enzymes(136), contractile 
proteins(247), protein kinases(48)  and energy metabolic enzymes(248-249) are involved in 
the development of I/R injury. However, the protein-protein interaction within these factors 
and the underlying molecular mechanisms of the development of I/R injury are still poorly 
understood. In order to develop novel effective therapeutic strategies for 
ischemia/reperfusion-induced contractile dysfunction, a better understanding of the  
mechanisms of I/R injury is required. In this study, we utilized proteomic methods to provide 
new insight into the molecular mechanisms of I/R injury.  
            The proteomic approach is becoming a powerful tool for profiling diseased states. 
Using proteomics to study the molecular mechanism of cardiac injury provides the 
characterization of alterations in comparative protein expression and information in protein-
protein interaction during cardiac injury. The results from proteomic approach allows 
investigators to have a comprehensive protein profile in certain pathological conditions. In 
addition, biomarkers and therapeutic targets can also be identified. Proteomic studies have 
been done for the comparative protein expression among different physiological and 
pathological conditions in the heart including ischemia preconditioning(250-251), congestive 
heart failure(252) and hypertrophy(253), and more than 400 proteins which are effected in 
cardiovascular diseases have been identified(44, 54, 254-256).  Studies suggest that these 
proteins are important in the regulation of the heart function as well as the pathogenesis of the 
cardiovascular diseases. (142-143).  
Most of proteomic studies focus only on proteins in the heart that display differential 
responses to different physiological or pathological conditions. There is few studies targeting 
comparison of different regions of the heart as it responds to various conditions. The left and 
right ventricles are two vital parts of the heart which perform different missions in the 
circulation. Despite both the left and right ventricles being well studied in their physiological 
role, the pathological roles of the ventricles are yet to be well demonstrated. In addition, since 
most of the studies mainly focus on the left ventricles in the pathological heart, the study of 
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the right ventricle has been overshadowed by the left ventricle.  Here, we demonstrate the 
comparison of the proteomic profile in the left and right ventricles of the I/R heart. The study 
presented in this thesis compares for the first time the changes of the left and right ventricle 
proteomes from hearts subjected to I/R injury. We demonstrated that there are proteomic 
differences between left and right ventricle in response to I/R injury. Those identified proteins 
participate in several different biological processes, such as, electron transport system (ATP 
synthase and cytochrome b-c1 complex), glycolysis (L-lactate dehydrogenase), stress 
management (peroxiredoxin 2 and peroxiredoxin 3), and contractile function (Myosin light 
chain 2, actin and myosin heavy chain 5). Our results suggest different regulation of these 
pathological processes, depending on the stage and the region of the cardiac injury, and are 
important for therapeutic design in cardiovascular research. The development of 
cardiovascular disease due to I/R injury results in significant alterations in the protein 
expression profile of the myocardium tissue. Further investigation of the relationship between 
these differentially expressed proteins and the development of the diseases would be very 
important for the understanding of the molecular mechanisms of the disease , the 
development of clinical therapies for cardiovascular disease, and improvement of the surgical 
procedures  
Numerous energy metabolic enzymes have been identified  in three of our studies 
(67, 257-258). We found in this study that energy metabolic enzymes such as : ATP synthase 
beta subunit (electron transport chain complex V), cytochrome b-c1 complex subunit 
(electron transport chain complex III), 24-kDa mitochondrial NADH dehydrogenase (electron 
transport chain complex I), cytochrome c oxidase subunit (electron transport chain complex 
IV),NADH dehydrogenase [ubiquinone] iron-sulfur protein 8 (electron transport chain 
complex I) and succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial decrease 
significantly under I/R condition. All of these enzymes are related to the most important 
process in ATP production, electron transport chain and citric acid cycle. This suggests that 
down-regulation of energy metabolic proteins and reduction of ATP generation are the key 
events in the development of I/R injury.  We also found that MLCK effects energy metabolic 
enzymes such as succinyl-CoA ligase. Studies have already shown that MLCK 
phosphorylates contractile proteins such as MLC1 and MLC2(259-260), which plays an 
important regulatory role in pathological conditions. In this study, we implicate that the 
MLCK pathway in the development of I/R-induced contractile dysfunction is  mainly 
involved in the regulation of energy production and contractile structural regulation. 
Inhibition of MLCK pathway using MLCK inhibitor ML-7 can reduce the phosphorylation of 
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energy metabolic proteins and contractile proteins. Hence, it improves the energy production 
and contractility during I/R.  
              Increasing activity of MMP-2 is implicated in a variety of pathological condition 
including atherosclerosis(261), ischemic heart diseases(262) and heart failure(263). Most of 
the MMP-2 studies have primarily focused on the extracellular function. It has already been 
shown that inhibition of MMP-2 protects the heart from I/R injury(264). In the present study, 
we used selective MMP-2 inhibitor MMP-2 siRNA to inhibit the MMP-2 protein expression. 
Using MMP-2 siRNA as tool we evaluated the pathological role of MMP-2 in the 
development of I/R injury. Isolated cardiomyocytes model was developed to study the 
intracellular function of MMP-2. We then investigated the proteomics of inhibition of MMP-
2 in isolated cardiomyocyte under aerobic condition, and we found that MMP-2 is involved 
in the regulation of the energy metabolic enzymes in normal physiological condition. It has 
been reported that energy metabolic enzymes are modulated in several cardiac disorder (140, 
155). However, the process of energy metabolic re-programming in the pathological heart 
still remians unclear. In this proteomic study, up-regulation of crucial energy metabolic 
enzyme such as cytochrome c oxidase, NADH dehydrogenase and ATP synthase were 
identified in the MMP-2 siRNA. Inhibition of MMP-2 increases the ATP synthase activity as 
well as the contractility of cardiomyocyte. In addition, using an isolated cardiomyocyte 
model, this study provides the first direct evidence for the intracellular function of MMP-2. 
This suggests that MMP-2 may degrade energy metabolic proteins in the mitochondria within 
the cardiomyocyte.  
                 Taken together, our studies reveal different responses of the left and right 
ventricles in the I/R heart. These responses are mainly targetting the modulation of contractile 
proteins and energy metabolic enzymes. It has been deminstrated that contractile proteins are 
regulated by MLCK and MMP-2(101). In this study, in order to investigate the regulatory 
role of MLCK and MMP-2 in energy metabolism during I/R, a combination method of 
selective inhibitors (ML-7 and MMP-2 siRNA) and proteomic approach is applied. Proteomic 
analysis of the I/R models with the inhibition of MLCK or MMP-2 allows investigators to 
evaluate the protein expression profile in I/R condition and find out which proteins are 
effected by the inhibition of MLCK and MMP-2. Our results show that proteins related to 
regulation of energy metabolism are MMP-2 targets during I/R, and protein kinase such as 
myosin light chain kinase (MLCK) is also involved in this process.  
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7. CONCLUSION 
 
           Our previous studies have demonstrated that the cardiac contractile proteins, such as 
MLC1 and MLC2, are subjected to posttranslational modifications (PTM) in response to I/R. 
The modification of these contractile proteins marks the protein for degradation by MMP-2 
with a consequent worsening of cardiac contractile dysfunction(20, 89). In our studies, energy 
metabolic proteins have been shown to contribute to cardiac I/R injury, which might be also 
associated with MLCK and MMP-2.  Our data provided a novel insight into the molecular 
mechanisms of cardiac I/R injury: during I/R, activated MLCK phosphorylates contractile 
proteins and energy metabolic proteins, and these modifications increase their degradation by 
intracellular MMP-2, resulting in reduction of ATP production and contractility, eventually 
leading to contractile dysfunction. 
    We expect that results from our studies will have implications in the clinical research 
of I/R injury from different pathological conditions.  In addition, selective MMP-2 inhibitor 
MMP-2 siRNA and MLCK inhibitor ML-7 show cardioprotective effects in response to I/R 
injury, suggesting novel promising strategies to reduce the impact of ischemic heart disease.  
Also, we have shown how the proteomic approach can be used to evaluate protein expression 
in the heart and to study the protein modulation related to cardiac dysfunction.   
                 
                My PhD project has five main objectives: 
1. To identify proteomic profile in the heart subjected to ischemia/reperfusion injury  
2. To compare in proteomic profile in right and left ventricle from heart subjected to 
ischemia/reperfusion injury  
3. To determine the effect of the Myosin Light Chain Kinase inhibitor ML-7 on the 
proteome of hearts subjected to ischemia/reperfusion injury 
4. To analyze the inhibition of MMP-2 gene expression with small interfering RNA in 
isolated cardiomyocytes by proteomic analysis, with the focus on the degradation of 
energy metabolic proteins by MMP-2 
5. To determine the cardioprotective effect of inhibition of MMP-2 using MMP-2 siRNA 
on isolated cardiomyocytes 
 
             Objectives are focusing on the alteration of proteome of the heart in the development 
of I/R injury.  Our finding presented here support that the modulation of energy metabolic 
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proteins play a key role in the development of I/R injury.  This can supplement our working 
mechanism of cardiac ischemia/reperfusion injury (101).  Moreover, a new strategy for 
inhibition of MMP-2 and MLCK were developed, and shows an effective protection from 
ischemia/reperfusion-induced cardiac contractile dysfunction. 
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8. LIMITATION AND FUTURE DIRECTIONS 
 
            There are a few limitations in this study.  First, the proteomic approach relies on the 
reproduction of two dimension electrophoresis, equal loading conditions and the software 
selection (such as PDQuest software) of significant protein targets.  In order to gain 
consistent positive and reproductive results, numbers of experiments need to be repeated and 
high criteria of exclusion setting are required.  When the target proteins are identified by MS, 
a more standard biochemistry analysis is necessary to verify these associations.  To date, one 
of the main problems in the proteomic study is lack of follow-up research.  Numbers of 
proteins are identified by proteomic analysis. However, most of the research groups do not 
intend to do the further research.  McGregor et al has provided a comprehensive review 
indicating major of limitations within the proteomics approach used in the cardiovascular 
research (265-266).  Second, purification/verification of cardiomyocyte has been performed 
in the in vitro model. However, contamination of other cell types still possibly affect the 
experimental results. Therefore, improvement of isolated cardiomyocyte in vitro model is 
necessary for further experiments. 
             Further direction for this study involves utilizing proteomics to investigate new 
insight into the molecular mechanism of cardiac injury which is important for the discovery 
of diagnostic and prognostic biomarker for heart disease.  The potential pharmacological 
target for developing new therapeutic strategies can also be identified by the proteomic 
approach.  In addition, the proteomic study constantly provides unexpected and exciting 
results with which we can have new directions to study the mechanisms of cardiac injury.   
             We have already demonstrated in the present and previous studies that MMP-2 and 
MLCK play significant roles in the development of I/R injury (202, 267-268). Inhibition of 
MMP-2 and MLCK using different pharmacological compounds has been shown to protect 
the heart from I/R injury. We suggest that the use of combination of pharmacological 
compounds targeting different factors would be an effective therapeutic strategy for the 
prevention and treatment of cardiovascular diseases. Based on the molecular mechanism of 
I/R injury, we have developed a combination of comprising inhibitor of MMP-2, MLCK, 
NOS and Rho kinase. This “drug cocktail” could act on separate factors and processes within 
the pathogenesis of the I/R injury, and show a powerful cardio protective effect.  The clinical 
trial for using these drug combinations during cardiac surgery may be a promising 
development and could lead to improvement in the operative and postoperative complications.     
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             As a long term study, ex vivo heart model and in vitro isolated cardiomyocyte model 
are necessary, but not enough.  Developing an in vivo model should be the further stage for 
our study on pharmacological design for the treatment of cardiac injury.  The in vivo model 
would be a vital step to verify the results from the ex vivo and in vitro model, especially the 
cardio protective effect from pharmacological compounds.  With all the comprehensive 
knowledge gained from three different models, clinical studies could lead to the next 
direction of therapeutic strategies. 
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